Skip to main content
RSC Advances logoLink to RSC Advances
. 2026 Nov 16. Online ahead of print. doi: 10.1039/d6ra09748k

Graphene quantum dot–gold nanocomposites for cancer biomarker and cell detection: interfacial design and analytical reliability

Chou-Yi Hsu a, Mohammed Hashim Mohammed b,✉, Maher Abdulrazzaq Al-hakeem c, Yasir Qasim Almajidi c,✉, Radhi K Al-Rashidi d, Irfan Ahmad e, Mirza R Baig f, Shakeel Ahmed Ansari g, Hader I Sakr h, Hamad AlMohamadi i,j
PMCID: PMC13772002  PMID: 43042082

Abstract

Graphene quantum dot–gold (GQD–Au) nanocomposites support the optical and electrochemical detection of cancer-associated biomarkers and cells; however, their analytical performance is difficult to evaluate when the material composition, recognition chemistry, and assay configuration change simultaneously. This review critically examines these platforms through a framework connecting material identity, interfacial organization, recognition-induced perturbations, and measurement validity. It distinguishes direct GQD–Au hybrids from supported and multicomponent architectures and compares nucleic-acid, protein, and intact-cell assays according to the constituent function, response mechanism, calibration, and biological-matrix testing. The reviewed evidence reveals architectural diversity concentrated around a limited set of targets, particularly carcinoembryonic antigen, while supporting materials, reporter placement, and capture procedures frequently contribute to the measured response. An approximately ninety-fold difference reported between buffer and serum detection limits within one prostate-specific-antigen platform illustrates the importance of matrix-specific validation. Multiplexed measurements demonstrate channel discrimination, while low cell-concentration limits require interpretation alongside specimen volume and capture recovery. The contribution of this review is an evidence-based organization of design relationships that separates demonstrated assay behavior from proposed mechanisms and inferred diagnostic utility. It identifies matched component controls, independent fabrication, reference-method comparison, and representative specimen testing as the priorities for establishing transferable performance. GQD–Au development should therefore be evaluated through interpretable recognition–transduction relationships and measurement validation under intended-use conditions, with the detection limits considered as one component of analytical quality.


This review links GQD–Au architecture to cancer-sensing responses and distinguishes the proposed mechanisms from demonstrated effects through component controls and study-specific analytical appraisal.graphic file with name d6ra09748k-ga.webp

1. Introduction

Cancer-associated measurements encompass molecular targets and intact cells, creating distinct requirements for recognition, sampling, and signal interpretation. Biosensing approaches offer opportunities to integrate these measurements into compact analytical platforms, but their diagnostic relevance depends on more than detecting low target concentrations.1–3 Recognition specificity, sample composition, and the relationship between the measured analyte and the intended biological question remain consequential.4,5 Accordingly, evaluating cancer sensors requires separating analytical responsiveness from diagnostic discrimination, a distinction relevant across both established and emerging biosensing formats.6,7

Graphene-based materials provide interfaces for organizing recognition elements and converting binding events into measurable responses.8–10 Within this family, graphene quantum dots (GQDs) combine nanoscale graphitic domains with chemically accessible surfaces and synthesis-dependent optical and electrochemical behavior.11,12 Functionalization can modify their dispersibility, receptor attachment, and interactions with other components, although these changes may not improve all performance attributes simultaneously.13 Cancer-oriented GQD research consequently spans different material preparations and biological objectives.14,15 Their roles as electrode modifiers, signal-generating components, and carriers for recognition elements should therefore be distinguished rather than treated as equivalent manifestations of a single material advantage.16

Gold introduces additional opportunities for biomolecule organization, electrical coupling, and optical interrogation.17,18 Its contribution depends on morphology, surface accessibility, and the position it occupies within the assay architecture. Combining gold with GQDs therefore creates an interfacial design problem rather than simply adding the properties of two components. The relevant question is how their spatial and chemical organization connects target recognition to the measured response.19,20 A hybrid may participate in capture, reporter attachment, signal generation, or several functions simultaneously. Without distinguishing these roles, a favorable response can be attributed to the nanocomposite even when supporting materials and assay organization make substantial contributions.

This attribution problem becomes more pronounced in multicomponent GQD architectures, where structural modification and assay redesign frequently occur together.21,22 Biological matrices introduce another layer of complexity because nonspecific adsorption and interfacial blocking may alter signals independently of intended recognition.23,24 Supporting polymers can influence immobilization and charge transport, further complicating the assignment of performance to GQD–Au interactions alone.25 The unresolved issue is therefore how to connect interfacial design with analytical reliability while retaining the conditions under which that connection is supported. A useful review should distinguish material descriptors, proposed transduction pathways, demonstrated analytical outcomes, and requirements for transferring performance beyond the initial assay.

Existing reviews provide broad accounts of GQD-containing biomedical nanocomposites,21 electroanalytical and optical sensing,22 cancer-oriented GQD biosensors,26,27 biosensing and bioimaging,28 gold-based optical cancer biosensors,29 and GQD functionalization and biomedical applications.30 These contributions establish the relevant material and application landscape. The present review adopts a narrower organizing question: what evidence connects the constituent arrangement of a GQD–Au cancer-sensing assembly to its measured response and analytical reliability? Its contribution is to integrate architecture classification, scrutiny of interfacial evidence, and study-specific analytical appraisal. Established validation principles71–75 provide the methodological basis rather than a claim of methodological novelty. Their application here distinguishes component-dependent amplification from demonstrated interfacial coupling, calculated detection limits from experimentally supported detection, and spiked-matrix performance from endogenous-analyte or clinical validation. This synthesis also connects the available evidence to GQD–Au-specific priorities in batch control, attachment stability, scalable fabrication, and point-of-care integration.

This approach produces three connected analytical outcomes. First, it distinguishes direct hybrids from supported and multicomponent systems, preventing performance from being assigned automatically to the GQD–Au pair. Second, it links recognition events to the observable actually measured, allowing fluorescence recovery, electrode-associated ECL, impedance changes, and capture-assisted cell responses to be interpreted within their respective architectures. Third, it evaluates detection limits alongside calibration intervals, specimen identity, and validation context, separating analytical responsiveness from diagnostic discrimination. These comparisons reveal concrete constraints: repeated CEA measurements broaden architectural coverage more directly than biological validation, matrix changes can substantially alter detection capability within one platform, and cell-concentration limits require sampling information to establish specimen-level meaning. The review therefore advances an evidence-based framework for extracting conditional design principles and identifying the experiments needed to establish their transferability. Sections 2 and 3 develop the material and mechanistic basis, Section 4 applies the framework to reported assays, and Section 5 translates the resulting evidence gaps into research priorities.

1.1. Literature scope and study-selection criteria

This review adopts a critical narrative approach to GQD–Au-containing platforms for the detection of cancer-associated biomarkers and cells. Literature was identified through Google Scholar using combinations of material-related terms (“graphene quantum dots” or “GQDs”) with gold-related terms (“gold nanoparticles,” “gold nanostars,” or “nanoporous gold”) and application-related terms (“cancer biomarkers,” “cancer cells,” “immunosensors,” or “aptasensors”). Readout-related terms included “fluorescence,” “electrochemistry,” and “electrochemiluminescence.” The primary cancer-sensing studies included in Section 4 span 2015–2025.76–89 Supporting references address constituent chemistry, interfacial characterization, transduction principles, and analytical validation and are distinguished from the primary cancer-sensing evidence.

Primary studies were eligible when both GQDs and gold participated in the functional sensing assembly and an experimentally measured response was reported for a cancer-associated biomolecule or cancer cell. Direct hybrids, supported assemblies, and multicomponent systems were considered, with their constituent arrangements and functions distinguished. Studies addressing non-cancer analytes, imaging or therapy without a detection assay, or assemblies lacking either GQDs or gold were excluded from the primary cancer-sensor comparison.

Table 2 summarizes the 14 included primary studies to compare recognition targets, interfacial architectures, readout mechanisms, analytical performance, and biological-matrix testing. Selection was not restricted to platforms reporting the lowest detection limits. Multiple CEA assays were retained because they permit a comparison of different architectures addressing the same target. Their frequency describes the composition of the included study set rather than the prevalence of CEA sensing throughout the literature. Accordingly, the review develops condition-dependent comparisons within this corpus without treating the selected studies as a quantitative census of the field.

Table 2. Comparative analytical characteristics and validation evidence of GQD–Au-containing platforms for the detection of cancer biomarkers and cellsa.

Target Architecture and readout Calibration and detection evidence Selectivity and sample-matrix evidence Additional analytical evidence Ref.
PCA3-associated target DNA Au–GQD-modified ITO; DNA hybridization monitored by CV Reported range: 100 fM–1 µM; LOD: 211 fM CYFRA-21 and cardiac-troponin-I DNA examined individually and with the target; measurements performed in PBS/ferro–ferricyanide electrolyte Experiments performed using different electrodes, n = 3; response time reported as 5 min, while optimization text describes saturation after 10 min; shelf life approximately 19 ± 1 days 76
miRNA-21, miRNA-155, and miRNA-210 AuNPs/GQDs/GO on a three-electrode array; multiplexed SWV Range: 0.001–1000 pM for each target; respective LODs: 0.04, 0.33, and 0.28 fM Single-base and triple-base mismatches, non-complementary sequences, and cross-channel interference examined; human-serum application Respective inter-electrode RSDs: 8.40%, 4.51%, and 9.43%, using 15 fabricated electrodes; target hybridization: 60 min; fabrication plus determination: 4 h 30 min; respective response retention after 21 days at 4 °C: 84.3%, 85.9%, and 89.5% 77
Glioma cells Ang-2-conjugated S-GQDs@Au–carbon nanospheres; pulse-assisted EIS Range: 100–100 000 cells mL−1; LOD: 40 cells mL−1 Selective glioma-cell detection demonstrated in a human-serum matrix; this matrix experiment should not be interpreted as evidence of patient-derived circulating-tumor-cell detection An external +0.6 V pulse promotes cell attachment to the recognition interface; the reported analytical performance therefore incorporates electrically assisted capture 87
PSA S-GQDs/gold nanostars on a screen-printed electrode; LSV immunosensing PBS range: 10 fg mL−1–50 ng mL−1; serum range: 100 fg mL−1–35 ng mL−1; respective LODs: 0.29 and 26 fg mL−1 Discrimination against eight interferents; measurements in PBS and neat human serum Human-serum recovery: 97–107%; the serum LOD is approximately 90 times higher than the buffer LOD, demonstrating substantial matrix dependence 78
CD44 Exfoliated GQDs decorated with AuNPs; antibody-based electrochemical sensing LOD: 1.17 fg mL−1 in PBS Anti-CD44 immobilization through EDC/NHS coupling; analytical detection demonstrated in PBS Electrochemical exfoliation provides GQDs with an approximate diameter of 3 nm, combined with approximately 15 nm AuNPs; the reported detection limit represents buffer-based performance 79
HepG2 cells Folic-acid/glutamic-acid-functionalized GQDs–Pd@Au; electrochemical cytosensing Cell-dependent electrochemical detection using a recognition-active and catalytically amplified hybrid Folic-acid-mediated cancer-cell recognition; application to human blood Glutamic-acid functionalization supports electrochemical activity, while Pd@Au contributes catalytic amplification; the measured response reflects the complete multicomponent architecture 89
CEA N,S-GQDs/gold nanostars; wash-free fluorescence-recovery immunoassay Dynamic range: 0.1 pg mL−1–10 µg mL−1; LOD: 64 fg mL−1 Common ions, amino acids, and PSA examined; human-serum application Human-serum recovery: 93–106%; wash-free fluorescence recovery provides a solution-phase assay format; stability and reproducibility were examined in the original study 84
CEA AuNPs/N-GQDs/rGO; label-free DPV immunosensing Range: 1 pg mL−1–500 ng mL−1; LOD: 0.13 pg mL−1 PSA, AFP, NGAL, CA19-9, CA125, and additional interferents examined; tenfold interference challenge; fetal bovine serum diluted 50-fold Calibration slope: −1.73 ± 0.054 µA per decade of concentration; inter-electrode RSD: 1.8%, n = 5; CEA incubation: 45 min in optimization study; 93.5% response retained after 5 days at 4 °C; serum recovery: 101–103% 81
CEA N,S-GQDs/Au–polyaniline nanowires; EIS immunosensing Range: 0.5–1000 ng mL−1, calibrated against logarithmic concentration; LOD: 0.01 ng mL−1 AFP, Tau, haemoglobin, l-cysteine, and l-glutamate examined; combined interference mixture increased response by approximately 11.4%; human serum diluted 10-fold Inter-electrode RSD: 6.8%, n = 5; antigen incubation: 60 min at room temperature; response retained at 4 °C: 98% ± 3%, 92% ± 4%, and 87% ± 4% after 10, 15, and 20 days, respectively; serum recovery: approximately 96.0–103.1% 80
p53 Poly-l-cysteine/GQDs/AuNP multilayer interface; SWV and DPV immunosensing SWV range: 0.000197–0.016 pM; DPV range: 0.195–50 pM; plasma range: 0.000592–1.296 pM; lower quantification limit: 0.065 fM Measurements in unprocessed human plasma and normal/malignant cell lysates Different calibration intervals were established for SWV, DPV, and plasma measurements; 0.065 fM is retained as a quantification threshold rather than being reclassified as an LOD 82
CA 15-3-associated immunoreactivity Gold nanospears assembled onto thiolated GQDs; SWV immunoassay Range: 0.16–125 U mL−1; reported detectable concentration: 0.11 U mL−1 Application to unprocessed human plasma and MCF-7 cell lysates SWV monitors antigen–antibody binding at the hybrid interface; the conservative target designation accommodates inconsistent antigen/antibody terminology 83
CEA GQDs@AuNP-labelled secondary antibody with a P5FIn/erGO capture interface; ECL Range: 0.1 pg mL−1–10 ng mL−1; LOD: 3.78 fg mL−1 Human-serum recovery testing; selectivity evaluated Reproducibility and stability evaluated; analytical amplification combines the P5FIn/erGO capture interface with GQDs@AuNP-labelled secondary antibodies 86
CEA Hydrazide-modified GQD–AuNP hybrids on glassy carbon; ECL immunosensing CEA-dependent ECL attenuation following immunoreaction Antibody–antigen recognition at the modified electrode Hybrid formation combines the ECL properties of hydrazide-modified GQDs with the biomolecular assembly capability of AuNPs; the response is interpreted through recognition-induced changes at the electrode interface 85
Glioma cells Ang-2/GQDs–nanoporous gold; label-free EIS Range: 1–106 cells mL−1; LOD: 1 cell mL−1 Anti-interference against multiple cell lines; spiked human-serum testing Response retention: 96% after 21 days of storage; measured cell concentrations in serum agreed with the added concentrations 88
CA-125 MXene/GQD/AuNP-modified GCE; electrochemical immunosensing Reported range: 0.1–1 nU mL−1; LOD: 0.075 nU mL−1; units retained as reported Real-sample testing and selectivity assessment CV, EIS, SWV, and DPV characterization; reproducibility evaluated 102
HER2 Gold-functionalized S,N-GQDs, cobalt porphyrin framework, and their conjugate; EIS immunosensing Three investigated interfaces gave LODs of 0.0327, 0.0454, and 0.1072 ng mL−1 Antibody-mediated recognition; human-serum application Formulation comparison; stability and reproducibility evaluated 103
HER2 Gold-functionalized GQD/porphyrin interfaces bearing aptamer or antibody; EIS Comparative detection performance of alternative recognition elements Spiked human serum Aptasensors showed improved detection limits, reusability, and storability relative to the corresponding immunosensors 104
PSA PANI/GQD/WOx/Au on graphenized screen-printed carbon electrode; PEC immunosensing Range: 0.1 pg mL−1–100 ng mL−1; LOD: 75 fg mL−1 Human serum without dilution or deproteinization Co-electrodeposition followed by AuNP modification; illumination-dependent photocurrent transduction 105
Glycan-overexpressing cancer cells N-GQD-wrapped AuNPs with Raman reporter and boronic-acid targeting ligand; SERS Targeted cell-surface recognition demonstrated by SERS imaging Recognition of glycan-overexpressing cancer cells Electromagnetic and chemical enhancement examined using experimental observations and computational modelling 106
MCF-7 cells PHAL-functionalized N,S-GQD/gold-nanostar interface; electrochemical cytosensing Range: 10–105 cells mL−1; LOD: 3 cells mL−1 Specificity assessed against other cancer-cell types Storage assessments extending to 100 days and reuse assessments extending to 30 cycles 107
BRCA1 AuNP@ZIF-8 capture interface with N-GQD-labelled secondary antibody; DPV Range: 1 pg mL−1–50 ng mL−1; LOD: 0.3 pg mL−1 Interference responses below 5%; spiked-serum recovery: 96.8–104.2% RSD: 3.8%; 92.5% signal retained after 30 days 108
Glioma cells GQD–nanoporous gold nanocomposite Angiopep-2-mediated recognition; label-free impedimetric detection Range: 1–106 cells mL−1; reported LOD: 1 cell mL−1; human serum containing added glioma cells; 96% response retained after 21 days of storage; interference evaluated using other cell lines 88
a

Entries summarize the reported analytical and validation evidence selected for comparison. Sensitivity denotes the calibration slope and is distinguished from LOD and quantification thresholds. Calibration intervals retain their original concentration-linear, logarithmic, or dynamic-range descriptions. Response times refer to the specified assay step; storage retention describes shelf stability and should not be interpreted as operational stability during repeated use. Differences in matrix dilution, electrolyte, electrode configuration, incubation procedures, and calibration models restrict direct comparisons. Accordingly, the table supports condition-dependent assessment rather than an unconditional ranking of sensor performance.

2. Material identity and interfacial organization of GQD–Au nanocomposites

2.1. Beyond particle size: the structural and electronic identity of GQDs

For cancer-sensing interfaces, GQD identity should be described through dimensions, graphitic-domain structure, oxidation, and accessible functional groups rather than particle size alone.31,32 Heteroatom incorporation and surface functionalization must also be distinguished because they generate different chemical environments for gold association and receptor attachment.33 Synthesis conditions can change these descriptors simultaneously, limiting attribution of improved sensing to a single variable.34 Their analytical relevance is therefore architectural: the GQD surface must support reproducible assembly, accessible recognition elements, and a measurable response. Comparisons should retain the relationship between preparation, surface chemistry, and assay configuration rather than assuming a universal size–performance relationship.35

2.2. Gold at the nanoscale: geometry, electronic regime, and intrinsic losses

Gold contributes receptor-attachment sites, electrical connectivity, and optical interactions, whose importance depends on its position within the sensing assembly.36 Metallic nanoparticles and atomically precise clusters possess different electronic regimes and should not receive interchangeable plasmonic descriptions.37,38 The nanostar geometry introduces additional optical and surface-accessibility variables, including branch dimensions and tip curvature.39 Ligand coverage further determines which regions remain available for GQD association and biofunctionalization.40 For the cancer assays examined here, gold morphology should consequently be interpreted alongside constituent placement and recognition chemistry. A larger signal cannot establish that a particular gold geometry is intrinsically superior when receptor loading, reporter arrangement, or measurement conditions also change.

2.3. GQD–Au formation routes and evidence for interfacial bonding

Formation chemistry determines how GQDs, gold, and recognition elements are organized before target exposure. Three processes should be distinguished: reduction of a gold precursor, attachment between the resulting constituents, and immobilization of biomolecular receptors. Ligand-controlled accessibility links these processes because groups involved in stabilization or anchoring may also determine the sites available for subsequent functionalization.41

2.3.1. In situ gold reduction by GQDs

A direct synthesis study demonstrates that starch-derived GQD preparations can produce and stabilize AuNPs after mixing with chloroauric acid without an additional reducing agent or surfactant.43 This provides a chemical precedent for using GQDs as both reducing and stabilizing components. The interpretation nevertheless remains preparation-specific: the study also identifies contributions from organic starch residues to stabilization. For cancer-sensor design, the relevant distinction is therefore between growth in the presence of the GQD preparation and assembly of independently synthesized particles. Precursor conversion, residual organic species, and changes in accessible surface groups should accompany the description of the synthetic route.

2.3.2. Au–S and Au–N association

Sulfur- and nitrogen-containing ligands provide chemically different routes to gold functionalization. Comparative experiments with thiol-, amino-, and carboxyl-containing ligands demonstrate that ligand identity affects both gold growth and surface coverage.42 In that study, sulfur components near 162.1 and 163.3 eV support thiolate attachment, whereas interpretation of nitrogen environments requires consideration of amine protonation and ligand transformation. These observations provide reference chemistry for evaluating functionalized GQD interfaces; they do not establish identical bonding in every GQD–Au sensor. Au–N coordination must also be distinguished from the amide linkage formed when GQD carboxyl groups are coupled to amino-functionalized antibodies or nucleic-acid probes.

2.3.3. Electrodeposition

Electrochemical deposition offers a separate route for constructing gold-bearing GQD electrodes. In a directly characterized example, GQDs were first assembled and electrochemically reduced on glassy carbon, followed by gold deposition at −0.2 V versus SCE for 40 s.44 This methodological precedent separates carbon-surface modification from gold growth. For cancer assays, the corresponding design variables include deposition potential and duration, GQD coverage, gold distribution, and the resulting accessibility of receptor-attachment sites.

2.3.4. Interfacial characterization

XPS should distinguish metallic-gold formation from evidence for constituent anchoring. Au 4f components can support precursor reduction, while ligand-specific S 2p or N 1s comparisons address attachment chemistry.42,43 Raman D- and G-band changes instead characterize perturbations of the carbon framework; an altered intensity ratio alone does not uniquely identify an Au–S, Au–N, or Au–C bond. Likewise, evidence of electronic alignment in GQD–gold composites addresses a different question from receptor immobilization.45 Structural, chemical, and electronic observations should therefore be connected to the actual sensing configuration before analytical improvement is assigned to a particular interfacial interaction.

Fig. 1 illustrates the morphological and compositional changes associated with the sequential electrodeposition of GQDs and gold on FTO for a colorectal-cancer-associated miR-223 biosensor. Panels a–c show the GQD-coated substrate at progressively higher magnifications, revealing nanosphere-like surface features. Panels d–f display the gold-decorated interface at the corresponding scales, enabling comparison of the surface texture before and after gold deposition. The EDAX spectrum of GQD/FTO in panel g provides the compositional reference, whereas panel h contains additional gold-associated signals following deposition. Together, these observations support the formation of a gold-bearing GQD electrode architecture. They establish morphology and elemental incorporation rather than a specific Au–S or Au–N bond; such chemical assignments require complementary evidence. The resulting interface subsequently supports thiolated capture-probe immobilization and miR-223 recognition.

Fig. 1. FESEM images of (a–c) GQD/FTO and (d–f) Au–GQD/FTO, with the corresponding EDAX spectra (g and h), respectively, illustrating the electrodeposited interface morphology and elemental composition. Reproduced with permission from ref. 46. Copyright © 2024, Elsevier B.V.

Fig. 1

GQD–Au sensing platforms can be described using three overlapping architecture categories. In a GQD–Au hybrid, the constituents are attached directly or through molecular linkers. In a supported assembly, another material organizes GQDs and gold on a shared surface. Multicomponent systems contain additional functional constituents, such as a second metal or a separate reporter (Fig. 2). The schematic illustrates these arrangements and the corresponding questions for component-control experiments. A supported or multicomponent system may also contain direct GQD–Au contacts; the categories describe constituent arrangement rather than mutually exclusive material classes. Attachment or coexistence alone does not demonstrate electronic coupling.

Fig. 2. Three overlapping GQD–Au architecture categories: (a) attached hybrids, (b) supported assemblies, and (c) multicomponent systems. Constituent arrangement guides control selection but does not establish electronic coupling.

Fig. 2

2.4. Interface in liquid: hydration, adsorption, and conditional material identity

The identity of a GQD–gold assembly in liquid cannot be inferred solely from its isolated or dried structure. Exposure to solution introduces hydration, ionic screening, and competitive adsorption, allowing the outer interface to evolve without necessarily altering the underlying constituents. General nanoparticle-interface frameworks distinguish the manufactured surface from the surface presented after environmental exposure. For GQD–gold assemblies, this distinction provides a conceptual basis for considering material identity as conditional on solution composition and exposure history.

Surface coating affects this evolution by governing the chemical environments available for adsorption.47 A hydrated ligand layer and a sparsely protected surface do not need to present equivalent interaction landscapes, even when their inorganic dimensions are similar. Surface charge also participates in a balance involving screening and molecular interactions; it should not be treated as an isolated predictor of interfacial behavior. Adsorption may modify the outer surface while leaving the constituent linkage intact, whereas interparticle association may change the organization of an otherwise chemically preserved assembly. Structural persistence and colloidal persistence therefore describe different aspects of material stability.

Protein adsorption introduces additional temporal complexity. Association, dissociation, lateral interactions, and conformational rearrangement can produce an interface that continues to evolve after initial exposure.48 The distinction between more persistent and more exchangeable corona components is consequently useful as a kinetic description, but it should not be interpreted as requiring two sharply separated physical layers. Furthermore, adsorbed-protein identity alone does not determine the structure of the resulting interface; orientation and conformation influence which molecular regions remain exposed.49

For sensing applications, nonspecific protein adsorption can influence both recognition and transduction. Adsorbed proteins may mask antibody or aptamer binding sites, alter receptor accessibility, and obstruct the approach of soluble targets. At electrochemical interfaces, this conditioning can also change redox-probe access and the measured resistance independently of specific binding. In optical assemblies, adsorption-induced changes in dispersion, aggregation, and fluorophore–metal separation can modify fluorescence. Surface protection therefore requires evaluation within the actual assay architecture. Experiments on ligand-coated AuNPs demonstrate that protein adsorption depends strongly on coating chemistry, with polyethylene-glycol- and zwitterion-functionalized surfaces resisting corona formation under the investigated conditions.47 These findings provide a design precedent rather than direct evidence that every GQD–Au interface exhibits equivalent antifouling behavior.

Ionic strength introduces an additional variable by changing electrostatic screening, colloidal interactions, and the accessibility of charged recognition interfaces. For nucleic-acid assays, salt composition can affect hybridization as well as interactions between the probe layer and electrochemical reporters. For impedance measurements, electrolyte conductivity must be distinguished from recognition-induced changes in interfacial resistance.68 Interfering biomolecules should consequently be evaluated both individually and in mixtures, using concentrations relevant to the intended specimen. Receptor-free controls, target-free matrix exposure, and comparisons between buffer and matrix-matched calibration help distinguish specific recognition from adsorption, conductivity changes, and background optical effects. Dilution and blocking procedures should be reported because they modify both matrix interference and the concentration presented to the sensor.

These concepts are derived from the broader nanoparticle literature and should not be interpreted as evidence that the GQD–gold architecture develops the same interfacial state.50 Their implication is narrower: constituent composition, manufactured organization, and environmentally conditioned surface identity are separate levels of description. Together, these levels establish the material foundation for the subsequent mechanistic framework, where recognition and signal generation can be examined without assuming that nominal composition uniquely defines the operative interface.

Table 1 organizes material descriptors into a hierarchy of interpretive dependencies rather than a catalogue of desirable properties. Its central implication is that nominal composition and average dimensions cannot, by themselves, establish the physicochemical identity of a GQD–gold assembly. Separating constituent structure, contact organization, and environmental conditioning helps expose assumptions underlying subsequent mechanistic interpretations.

Table 1. Structural and interfacial evidence in GQD–Au cancer-sensing platforms: formation routes, observed responses, and interpretive limits.

Cancer target and platform Formation route and constituent arrangement Reported structural or interfacial evidence Observed functional response Interpretation and design significance Ref.
miR-223; Au–GQD-modified FTO electrode Sequential electrodeposition of a GQD layer and gold on FTO, followed by thiolated capture-probe immobilization FESEM compares the surface morphology before and after gold deposition; EDAX identifies the additional gold-associated signals; and AFM characterizes the surface topography CV, DPV, and EIS track the electrode modification and subsequent probe–target hybridization Supports formation of a gold-bearing GQD electrode and a recognition–responsive interface. Morphology and elemental composition do not establish a particular GQD–Au bonding configuration 46
Neuron-specific enolase; anti-NSE/amine-N-GQD–AuNP fluorescent assembly Hydrothermal preparation of amine-functionalized N-GQDs, covalent antibody conjugation, and assembly with AuNPs Optical characterization includes emission–absorption overlap; supporting measurements include Stern–Volmer analysis and time-resolved photoluminescence NSE-dependent fluorescence recovery from the quenched nanoprobe Links recognition to an optical response in a donor–acceptor assembly. The proposed nanosurface energy-transfer mechanism should be assessed using the combined optical evidence rather than fluorescence intensity alone 60
CEA; PtPd/N-GQD@Au-modified glassy carbon electrode Hydrothermal preparation of PtPd supported on N-GQDs, followed by amino functionalization and assembly with AuNPs TEM and EDX characterize the multicomponent structure; component-control amperometry compares catalytic responses; and EIS and CV monitor biomolecular assembly The complete composite gives the largest cathodic H2O2-reduction response; antibody immobilization, blocking, and CEA binding progressively increase resistance and attenuate voltammetric current Distinguishes formulation-dependent catalytic amplification from recognition-associated blocking. The multicomponent response does not isolate the contribution of individual GQD–Au contacts 62
CA19-9; porous-carbon/AuNP electrode with aptamer/POM/GQD–Au nanotags A porous-carbon/PEI-capped AuNP capture interface is combined with separate aptamer/polyoxometalate/GQD–citrate-capped AuNP reporter assemblies The defined assay architecture places the immobilized antigen on the capture electrode and the redox-active POM within the reporter assembly The POM-derived DPV signal decreases with increasing CA19-9 concentration in the competitive assay Identifies reporter recruitment as a determinant of signal magnitude. The response should be interpreted through competitive binding and reporter loading; it does not independently establish GQD–Au charge-transfer enhancement 64

3. From recognition to readout: mechanistic framework and sensor design logic

3.1. Recognition as an interfacial perturbation: accessibility, occupancy, and kinetic compatibility

Recognition chemistry determines whether the assembled interface converts target capture into a measurable perturbation. Antibody and aptamer formats impose different requirements for immobilization, orientation, and functional accessibility.51,52 Increasing receptor loading is therefore useful only when recognition activity is preserved. For nucleic-acid sensing, probe attachment must accommodate hybridization and the accompanying change in reporter access; solution-phase affinity alone does not describe the behavior of an immobilized recognition layer.53,54 Incubation time and target transport additionally influence occupancy and calibration.55 In the reviewed protein, nucleic-acid, and cell assays, these variables should be considered together with GQD–Au organization, rather than treating recognition specificity as an automatic consequence of nanocomposite formation.

3.2. Optical transduction: connecting recognition geometry with emission

Optical GQD–Au assays should specify whether recognition changes excitation, excited-state relaxation, optical attenuation, or the population of contributing emitters. Metal-associated fluorescence enhancement and quenching depend on geometry and spectral interactions, so intensity changes alone do not establish a particular energy-transfer pathway.56,57 Absorption-dependent inner-filter contributions must also be separated from changes in excited-state decay.58 Electrochemiluminescence requires a distinct interpretation because excitation arises through electrode-driven reactions rather than external illumination.59

A direct cancer-sensing example combines antibody-functionalized amine-N-GQDs with AuNPs for neuron-specific enolase detection.60 The authors describe a nanosurface-energy-transfer-based fluorescence-recovery assay, reporting a 16 min response and an LOD of 0.09 pg mL−1. This example connects surface functionalization and recognition geometry with the measured optical response. Its mechanistic interpretation should be assessed using the accompanying spectroscopic evidence rather than inferred from the low detection limit.

3.3. Electrochemical transduction: distinguishing interface blocking from reporter amplification

Electrochemical cancer assays require identification of the process sampled by the measurement. An increase in charge-transfer resistance can reflect restricted redox-probe access or interfacial blocking, while equivalent-circuit fitting alone does not establish a microscopic GQD–Au transfer pathway.61,62 Capacitive responses additionally depend on changes in hydration, ion distribution, and the recognition-layer dielectric environment.63

Reporter-amplified sensing provides a contrasting architecture. A 2025 competitive CA19-9 aptasensor combines a porous-carbon/gold capture interface with polyoxometalate/aptamer/GQD-decorated gold nanotags.64 DPV interrogates the redox-active polyoxometalate, and the response decreases with increasing target concentration. The measured signal therefore depends on competitive recognition and reporter recruitment, rather than directly measuring intrinsic nanocomposite conductivity. Voltammetric settings also influence the observed response and must be retained when comparing analytical performance.65 These distinctions connect the electrical observable to the actual assay configuration.

Fig. 3 connects component-dependent electrocatalysis with recognition-induced changes in a CEA immunosensor. Panel A compares amperometric H2O2-reduction responses at bare GCE and electrodes modified with N-GQDs, Au nanoparticles, PtPd/N-GQDs, and PtPd/N-GQDs@Au. The complete composite produces the largest cathodic response, supporting its function as an electrocatalytic amplification platform. Panel B shows decreased charge-transfer resistance after composite deposition, followed by increasing resistance upon sequential antibody immobilization, BSA blocking, and CEA binding. Panel C provides complementary cyclic-voltammetric evidence, with increased current after composite modification and progressive attenuation following biomolecular assembly. Together, these measurements distinguish catalytic signal amplification from recognition-associated interfacial blocking. The component comparisons establish formulation-dependent performance, while the electrochemical responses alone do not uniquely identify electron transfer across individual GQD–Au contacts.

Fig. 3. (A) Component-dependent amperometric H2O2 reduction. (B) EIS and (C) cyclic voltammetry plots tracking the immunosensor assembly and CEA binding at the PtPd/N-GQD@Au-modified electrodes. Reproduced with permission from ref. 62. Copyright © 2017, Elsevier B.V.

Fig. 3

3.4. Mechanistic attribution: study-specific controls and orthogonal evidence

The relationship between GQD–Au interfacial structure and sensing performance should be evaluated through complementary structural, spectroscopic, and functional evidence. Constituent distribution establishes the organization of the sensing assembly, while chemically resolved measurements can support specific anchoring interactions. A target-dependent optical or electrochemical response then establishes analytical responsiveness under the tested conditions. Connecting these observations to a particular transduction pathway requires distinguishing chemical attachment, recognition-induced interfacial changes, and electronic interactions between the constituents.66,67

The N,S-GQD/Au–polyaniline CEA platform illustrates how different measurements support different aspects of this relationship.80 An S 2p contribution near 162.5 eV, together with changes in the Au 4f spectrum, supports Au–S attachment. EIS measurements subsequently show increased resistance following antibody immobilization and antigen binding. Comparisons involving Au–polyaniline without N,S-GQDs, pristine-GQD interfaces, and antibody-free assemblies further support the contributions of surface functionalization and specific recognition. These observations connect assembly chemistry with sensing behavior. However, the measured charge-transfer resistance characterizes the electrode–electrolyte interface and does not independently quantify electron transfer across individual GQD–Au contacts. Equivalent-circuit interpretation must therefore account for redox-probe accessibility, interfacial blocking, and transport contributions.68

For optical sensing, fluorescence intensity and excited-state dynamics provide complementary information. In the NS-GQD/gold-nanostar CEA assay, fluorescence recovery constitutes the measured analytical response, whereas the authors describe the transduction using a combined Förster–Dexter framework.84 The associated supporting information includes time-correlated single-photon-counting comparisons with and without the quencher. Such measurements help assess changes in excited-state relaxation, but lifetime shortening alone does not uniquely identify energy transfer, electron transfer, or metal-associated nonradiative decay. Interpretation should integrate decay behavior with spectral overlap, absorption, quantum yield, and fluorophore–metal separation. Absorption-dependent attenuation also requires attention because inner-filter effects can change fluorescence intensity and calibration behavior without representing an additional excited-state transfer pathway.58

Component-control experiments strengthen structure–performance attribution when constituent loading, receptor coverage, supporting matrix, and measurement conditions are matched. Relevant comparisons include isolated constituents, their physical mixture, the assembled hybrid, receptor-free interfaces, and non-target exposure. Independent characterization of biofunctionalization helps distinguish increased attachment capacity from preserved recognition activity.69,70 Removing GQDs or gold can simultaneously alter accessible area, morphology, and receptor organization; therefore, the resulting signal difference establishes the contribution of the tested formulation more directly than a unique microscopic coupling mechanism.

Accordingly, structural characterization, measured analytical responses, and mechanistic interpretation should remain explicitly connected but distinguishable. XPS supports chemical-state assignments, lifetime measurements probe excited-state relaxation, EIS characterizes interfacial electrical behavior, and matched controls constrain constituent and recognition contributions. Agreement among these measurements provides a stronger basis for relating GQD–Au organization to sensing performance than any individual characterization result.

The attribution framework is applied study-by-study in Table 2 by separating analytical performance, independent fabrication reproducibility, component-control evidence, matrix validation, reference-method agreement, stability, and interference testing. Repeated measurements on one electrode are distinguished from measurements across independently prepared electrodes. Likewise, stepwise electrode-assembly measurements are distinguished from matched component controls, and agreement with the recovery of an added concentration is distinguished from comparison against an independent reference method. These distinctions determine the scope of the conclusions supported by each study.

3.5. Analytical design: linking response functions to measurement validity

Analytical design translates an attributed response into a measurement procedure with a defined purpose. For GQD–Au sensors, the relevant response function relates the measured observable to target concentration or an explicitly defined cell-associated measurand under specified conditions. Signal brightness, conductivity, and amplification are therefore intermediate properties; their analytical value depends on calibration behavior, variability, and the decision the measurement is intended to support.

Sensitivity should be distinguished from signal magnitude. A larger output may coexist with greater background variability, drift, or reduced usable range. Similarly, a lower calculated detection limit does not necessarily indicate better quantification or more reliable discrimination between samples.71 Detection capability, precision, selectivity, and response range should consequently be considered together, rather than ranked through a single favorable metric.72

The calibration model should reflect the response regime actually interrogated. Local slope, heteroscedasticity, saturation, and time dependence may influence uncertainty differently across the measurement range. Independent sensor preparations are particularly relevant because repeated readings from one interface estimate a narrower source of variability than repeated fabrication and measurement. Validation should also distinguish the fitting of a response function from testing its performance using independent materials or samples.73

Selectivity requires an operational definition. Recovery or agreement after target addition can support aspects of measurement performance but does not independently establish discrimination against competing species. Likewise, a cell-associated signal may represent captured cell number, accessible binding sites, or contact-dependent response; these measurands should not be treated as equivalent without justification. Method-validation principles provide a framework for defining these distinctions and evaluating their consequences.74

Performance criteria and evaluation procedures should be specified before interpreting favorable results, including replication, acceptance limits, and treatment of departures from the calibration model.75 This completes the design framework: recognition generates a perturbation, transduction converts it into an observable, and validation determines its measurement value. Section 4 can then apply these criteria to the experimental evidence without repeating the underlying framework.

Detection-limit appraisal should consistently distinguish the lowest investigated concentration, the lowest calibration standard, the calculated LOD, and the lowest concentration independently demonstrated to be detectable. For a locally linear response, the estimated signal increment at the LOD can be assessed as CLOD, using dimensionally consistent slope and concentration units. For logarithmic or nonlinear calibration, the corresponding response function must instead be evaluated explicitly. In either case, the predicted response should be compared with experimentally characterized blank variability and measurement uncertainty; regression fit alone does not establish low-concentration detectability.

4. Cancer biomarker and cell detection: critical appraisal of experimental evidence and cross-study trends

4.1. Nucleic-acid detection: single-target hybridization and multiplexed measurement

Nucleic-acid sensing illustrates how the contribution of GQD–Au interfaces depends on their integration with capture probes, electrode configurations, and electrochemical reporters. An Au–GQD-modified indium–tin oxide electrode was developed for the hybridization-based detection of a PCA3-associated target sequence, reporting a detection limit of 211 fM, a five-minute response, and a sensor shelf life of approximately 19 ± 1 days.76 Reporting response time and storage stability, alongside detection capability, provides a more informative assessment than an isolated detection limit. However, the stated concentration interval extends from 100 fM to 1 µM, with its lowest concentration falling below the reported detection limit. This relationship requires interpretation through the calibration procedure and detection-limit calculation: inclusion of a concentration in an investigated interval does not establish that it can be detected reliably or quantified with acceptable uncertainty. Moreover, sequence detection should remain distinct from measurement of endogenous PCA3 in clinical specimens.

The AuNPs/GQDs/GO platform for miRNA-21, miRNA-155, and miRNA-210 employed a three-electrode array and distinguishable electrochemical reporters to achieve multiplexed measurement.77 Hybridization decreased the corresponding voltammetric currents, while the electrode configuration and reporter selection provided channel discrimination. Consequently, multiplexing was a property of the integrated assay rather than an intrinsic capability of the GQD–Au combination. The respective detection limits were 0.04, 0.33, and 0.28 fM, whereas the reported calibration interval began at 0.001 pM, equivalent to 1 fM. Detection limits below the lowest calibration standard are not inherently inconsistent, but their reliability depends on the statistical procedure and verification near the estimated detection threshold. The unequal limits also show that a shared material platform does not ensure equivalent analytical performance across recognition channels.

These studies establish complementary capabilities: single-target hybridization with reported operational characteristics and simultaneous measurement with differentiated channels.76,77 Their comparison supports a design principle in which the composite, recognition layer, and readout architecture must be evaluated together. For multiplexed systems, channel-specific calibration, cross-reactivity, and interference during simultaneous target variation are particularly consequential. Human-serum application in ref. 77 increases the relevance of the assay environment, but neither low detection limits nor multiple channels alone establish improved cancer classification. Diagnostic benefit requires a separate assessment of whether the combined measurements provide information beyond individual biomarkers.

Fig. 4a presents cyclic voltammograms of an Au–GQD-modified ITO sensing interface exposed to different concentrations of a PCA3-associated target DNA sequence, illustrating how hybridization is translated into an electrochemical response. Its inset summarizes the concentration-dependent current changes. Panel (b) relates the measured current to target concentration on a logarithmic axis, providing the calibration underlying the reported detection limit. Together, these panels exemplify single-target hybridization sensing, in which an immobilized capture probe and electrochemical interrogation jointly determine analytical performance. However, the lowest investigated concentration, 100 fM, falls below the reported detection limit of 211 fM; therefore, its inclusion in the calibration interval does not establish reliable detection or quantification at that concentration. Furthermore, concentration-dependent current changes do not independently isolate GQD–Au coupling or demonstrate measurement of endogenous PCA3 in clinical specimens.

Fig. 4. PCA3-associated target DNA sensing: (a) concentration-dependent cyclic voltammograms with the current responses (inset) and (b) current calibration versus target concentration plot on a logarithmic axis. Under the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/). Copyright © 2024, the authors.

Fig. 4

4.2. Protein immunosensing: interfacial architecture and matrix-dependent performance

Protein immunosensors employ diverse GQD–Au architectures, but their analytical performance reflects the combined effects of antibody immobilization, supporting materials, measurement conditions, and sample composition. The approximately ninetyfold buffer-to-serum difference is retained here as an illustrative observation from a single study. It should not be interpreted as a typical matrix penalty for GQD–Au sensors or generalized to other sensing architectures. The reported LODs therefore lie approximately 34-fold and fourfold below the lowest calibrants. As for the multiplexed microRNA assay,77 these values should be distinguished from experimentally demonstrated detection at the stated concentrations. An LOD below the lowest calibrant is not intrinsically invalid, but its interpretation requires the calculation procedure, relevant blank variability, and independent measurements near the estimated threshold. The approximately ninetyfold increase in LOD from buffer to serum also demonstrates matrix-dependent detection capability. Serum recoveries of 97–107% provide complementary evidence of measurement performance at the tested concentrations but do not independently validate either extrapolated detection limit.

For CD44, exfoliated GQDs of approximately 3 nm were integrated with approximately 15 nm AuNPs, with antibody immobilization through EDC/NHS coupling.79 The reported buffer detection limit of 1.17 fg mL−1 demonstrates analytical responsiveness under those conditions. However, particle dimensions and a low detection limit do not independently establish the contribution of interfacial coupling or preserved antibody activity. These contributions require evaluation through component controls and characterization of the functionalized recognition layer. The buffer result should therefore be interpreted within its own assay context rather than ranked directly against serum-based measurements.

CEA sensing further reveals how supporting components participate in analytical performance. GQD-decorated Au–polyaniline nanowires produced an impedimetric response associated with increased charge-transfer resistance after immunocomplex formation, reporting a detection limit of 0.01 ng mL−1 and human-serum recoveries of approximately 96–103%.80 An AuNPs/N-GQDs/rGO interface reported a lower limit of 0.13 pg mL−1 and application in fetal bovine serum.81 This difference does not isolate the effects of nitrogen incorporation, gold organization, or rGO because several architectural and experimental variables differ simultaneously. Moreover, fetal bovine serum and human serum represent distinct validation environments. These studies demonstrate alternative integration strategies, while attribution of performance to individual material features remains dependent on matched comparisons.

The p53 platform reported different calibration intervals for square-wave and differential-pulse voltammetry, illustrating that instrumental interrogation contributes to the stated analytical range.82 Its reported lower quantification limit of 0.065 fM should remain explicitly identified as quantification metric rather than be treated as interchangeable with detection limits. The gold-nanospear/thiolated-GQD platform extended CA 15-3-associated measurements to unprocessed plasma and MCF-7 lysates, with a reported detectable concentration of 0.11 U mL−1.83 Interpretation requires a clear distinction between the immobilized recognition species and the measured analyte. Across these protein assays, the most useful comparison therefore concerns how architecture supports recognition and retains performance in the intended matrix, rather than which platform reports the smallest numerical limit.

Fig. 5 illustrates the concentration- and matrix-dependent response of the S-GQD/gold-nanostar PSA immunosensor.78 Panel (a) shows decreasing LSV peak currents with increasing PSA concentration, consistent with recognition-associated restriction of the electrode response. Panel (b) presents the overall response in PBS, while panels (c) and (d) resolve separate low- and high-concentration calibration regimes, spanning 10 fg mL−1–0.15 ng mL−1 and 0.15–50 ng mL−1, respectively. Panels (e) and (f) show the corresponding calibrations in neat human serum over 0.1 pg mL−1–0.2 ng mL−1 and 0.2–35 ng mL−1, respectively. These distinct regimes indicate that sensitivity must be interpreted within the relevant concentration interval and matrix rather than represented by a single slope across the entire range.

Fig. 5. PSA immunosensing: (a) concentration-dependent LSV responses, (b) overall PBS calibration, (c) low- and (d) high-concentration PBS calibrations, and (e and f) corresponding neat-serum calibrations. Reproduced with permission from ref. 78. Copyright © 2021, Elsevier B.V.

Fig. 5

The calibration equations also require dimensional scrutiny. In panel (c), the displayed equation, Y = −0.0098X + 0.003, accompanies a current axis labelled in mA, although its intercept and endpoint are consistent with current expressed in A. Interpreting the equation in A gives approximately 1.53 mA at 0.15 ng mL−1, matching the plotted endpoint. Under this interpretation, extrapolation to the reported PBS LOD of 0.29 fg mL−1 implies a current difference of approximately 2.8 nA. Literal application of the displayed mA units instead gives approximately 2.8 pA but fails to reproduce the plotted current scale. Similar equation-axis inconsistencies appear in panels (e) and (f). Furthermore, the reported PBS and serum LODs lie below their respective lowest calibrants. These observations require caution: neither regression agreement nor an extrapolated signal increment establishes detectability without appropriate blank variability, drift assessment, electrode-to-electrode reproducibility, and independent measurements near the calculated thresholds.78

4.3. CEA optical readouts: fluorescence recovery and electrochemiluminescence architectures

CEA provides a common target for examining how GQD–Au assemblies support different optical responses. The N,S-co-doped-GQD/gold-nanostar immunosensor employed a wash-free fluorescence-recovery configuration, reporting a detection limit of 64 fg mL−1, a concentration interval of 0.1 pg mL−1–10 µg mL−1, and human-serum recoveries of 93–106%.84 Increasing fluorescence with increasing CEA links recognition to a change in the fluorophore–quencher arrangement. Nevertheless, the reported FRET–DET interpretation should be distinguished from the analytical observation itself. Establishing the respective contributions of transfer pathways requires evidence beyond intensity recovery, including appropriate spectroscopic and geometrical controls. The wash-free format offers a potentially simpler workflow, but its analytical value also depends on background signals and interference from components remaining in the measurement mixture.

Hydrazide-modified GQD–AuNP hybrids immobilized on a glassy carbon electrode produced a contrasting response: increasing CEA decreased electrochemiluminescence intensity.85 The assay reported a concentration range of 0.02–80 ng mL−1 and a detection limit of 0.01 ng mL−1. The response was attributed to increased electron-transfer resistance following immunoreaction. This interpretation connects recognition to electrode-associated excitation, rather than to fluorescence modulation under external illumination. Accordingly, the opposite signal directions in ref. 84 and 85 reflect different assay architectures and excitation processes; they do not imply contradictory intrinsic behavior of GQD–Au materials. Mechanistic assessment should determine whether changes in electron transfer, reactant accessibility, or other interfacial processes account for the observed ECL response.

A second ECL assay distributed capture and reporting functions between a poly(5-formylindole)/electrochemically reduced graphene oxide matrix and GQDs@AuNP labels carrying secondary antibodies.86 Its reported range was 0.1 pg mL−1–10 ng mL−1, with a detection limit of 3.78 fg mL−1 and human-serum application. Here, the nanocomposite served within a multicomponent labelled assay, whereas85 incorporated the hybrid into the electrode-associated sensing interface. This distinction is central to performance attribution: the capture matrix, secondary-antibody labels, and assay sequence all contribute to the final measurement.

Together, these CEA systems demonstrate that the functional position of the hybrid determines how recognition influences optical output.84–86 A meaningful comparison should therefore consider signal direction, excitation route, label placement, assay steps, matrix, and uncertainty alongside detection limits. The resulting design principle is to select architecture according to the perturbation that recognition can generate and the workflow it can support, rather than assuming that one optical modality is universally superior.

4.4. Intact-cell detection: recognition, capture, and sampling constraints

Intact-cell detection introduces sampling and capture requirements that are not present in the same form for soluble biomarkers. The Ang-2-functionalized S-GQDs@Au–carbon-nanosphere platform reported glioma-cell detection over 100–100 000 cells mL−1, with a detection limit of 40 cells mL−1.87 An applied +0.6 V pulse was used to accelerate cell attachment, making the capture procedure an explicit contributor to assay performance. Evaluation should therefore distinguish improvements in delivery or attachment from improvements in transduction per captured cell. Recognition-dependent capture also requires comparison with nonspecific attachment under the same electrical and incubation conditions.

The GQD–nanoporous-gold platform represents a related architectural strategy for glioma-cell sensing.88 Comparison with ref. 87 should address how the porous interface affects accessible recognition sites, cell contact, and electrochemical interrogation. However, differences in architecture alone cannot establish improved detection capability. A quantitative comparison requires the concentration range, detection-limit procedure, specimen volume, capture conditions, and matrix-validation results to be evaluated on a consistent basis. The relevance of either platform to circulating glioma-cell measurement additionally depends on demonstrating performance with representative specimens rather than inferring that capability from cultured-cell experiments.

The FA/Glu-functionalized GQD–Pd@Au platform reported HepG2-cell detection over 3–105 cells mL−1, a detection limit of 2 cells mL−1, and application in human blood.89 Its response combined recognition by functionalized GQDs with redox activity and catalytic amplification associated with the metallic component. It should therefore be classified as a multicomponent, bimetallic platform rather than evidence for an isolated GQD–Au contribution. The lower reported concentration limit relative to87 involves a different cell type, recognition strategy, capture process, and readout.

Fig. 6a presents concentration-dependent Nyquist responses without electrical stimulation, establishing the baseline for evaluating the capture protocol. Panel (b) shows responses following a +0.3 V pulse, with enhanced impedance changes relative to the unstimulated condition. Panel (c) presents the responses at +0.6 V, the potential selected for subsequent measurements. Panel (d) shows responses at +0.9 V, where the comparatively smaller changes at high cell concentrations indicate that stronger stimulation does not consistently improve detection. Panel (e) compares percentage changes in charge-transfer resistance across cell concentrations and applied potentials, demonstrating that assay performance depends on the electrical capture conditions. Together, these observations connect intact-cell sensing to capture-dependent interfacial perturbations. Nevertheless, impedance enhancement alone cannot distinguish increased specific attachment from changes in transduction or nonspecific adhesion. Mechanistic attribution therefore requires independent enumeration of captured cells and matched attachment controls, while interpretation at low concentrations additionally requires specimen volume, capture recovery, and sampling variability.

Fig. 6. Glioma-cell Nyquist responses following capture potentials of (a) 0 V, (b) +0.3 V, (c) +0.6 V, and (d) +0.9 V and (e) percentage changes in the charge-transfer resistance. Reproduced with permission from ref. 87. Copyright © 2021, Elsevier B.V.

Fig. 6

At low cell concentrations, specimen volume is essential to interpretation. A concentration expressed in cells mL−1 does not specify how many cells actually enter the assay, and random sampling may produce specimens containing no target cells. Detection-limit assessment should therefore account for processed volume, any enrichment step, capture recovery, and variability in the number of cells delivered to the sensing interface. Surface-marker heterogeneity and background-cell interference further determine whether a cell-associated signal supports selective enumeration.

Finally, p53 and CA 15-3 measurements in lysates82,83 must remain distinct from intact-cell detection. Lysate assays quantify released molecular constituents, whereas cell-oriented assays connect signals to cellular capture or concentration. These approaches provide complementary biological information but require different validation criteria. Progress in intact-cell sensing consequently depends on connecting reported concentration sensitivity to specimen-level detection probability, selective capture, and independently verified cell counts.

4.5. Expanded target and transduction coverage: CA-125, HER2, photoelectrochemistry, and Raman readouts

GQD–Au-containing cancer assays extend beyond the target distribution represented by the initial study set. In a 2024 study, a CA-125 immunosensor was fabricated by combining MXene, GQDs, and AuNPs on a glassy carbon electrode.102 This supported architecture expands ovarian-cancer biomarker coverage while illustrating the importance of constituent attribution: MXene provides the supporting interface, whereas GQDs and AuNPs contribute to the electrochemical and biofunctional assembly. Its performance should therefore be evaluated as that of a multicomponent sensing layer rather than assigned exclusively to GQD–Au coupling.

HER2 detection provides additional opportunities to compare material organization and recognition chemistry. Centane and Nyokong investigated gold-functionalized sulfur/nitrogen-doped GQDs, a cobalt porphyrin binuclear framework, and their conjugate as antibody-bearing impedimetric interfaces.103 The study reports different detection limits for the tested formulations, demonstrating that nominal inclusion of GQDs and gold does not uniquely determine performance. A subsequent comparison of aptamer and antibody recognition on related interfaces found differences in detection capability, regeneration, and storage behavior.104 These results identify recognition-element selection as a consequential variable alongside nanocomposite composition.

Photoelectrochemical sensing introduces illumination-dependent charge generation into the analytical architecture. In 2026, a study reported a PSA immunosensor employing a co-electrodeposited polyaniline/GQD/tungsten-oxide material subsequently decorated with AuNPs.105 The reported range is 0.1 pg mL−1–100 ng mL−1, with an LOD of 75 fg mL−1, and measurements were demonstrated in human serum without dilution or deproteinization. Because the photoactive assembly contains several constituents, photocurrent enhancement must be interpreted through illumination conditions, component controls, and recognition-induced changes at the complete interface.

Raman-based detection provides a distinct optical example. Nitrogen-doped GQD-wrapped AuNPs were functionalized with 4-nitrobenzenethiol as a reporter and 4-mercaptophenylboronic acid as a targeting element for SERS imaging of glycan-overexpressing cancer cells.106 This work demonstrates cell-surface recognition through a Raman-reporter architecture. Its imaging outcome should remain distinct from concentration-calibrated biomarker quantification.

Recent studies further expand intact-cell and protein coverage. A 2025 N,S-GQD/gold-nanostar platform functionalized with PHAL reports MCF-7 detection over 10–105 cells mL−1, with an LOD of 3 cells mL−1 and assessments extending to 100 days of storage and 30 reuse cycles.107 A 2026 BRCA1 immunosensor places AuNP-decorated ZIF-8 at the capture interface and N-GQDs on secondary-antibody labels.108 This spatially separated configuration illustrates assay-level integration of gold and GQDs without requiring direct contact between them.

Coverage boundaries remain important for AFP, exosomes, and colorimetric formats. GQD-based studies have demonstrated exosomal-miRNA detection109 and multiplexed AFP/CA125 measurement,110 but these architectures should not automatically be classified as GQD–Au hybrids. Likewise, the existence of GQD–Au colorimetric chemistry does not establish a cancer-specific colorimetric assay. These adjacent developments identify opportunities for extending the reviewed architectures while preserving a consistent requirement that both constituents participate in the cancer-sensing assembly.

4.6. Critical assessment of evidence quality and diagnostic relevance

The studies examined in Sections 4.1–4.4 demonstrate analytical responses to selected cancer-associated nucleic acids, proteins, and intact cells, but the significance of these responses depends on the experimental question each assay addresses. Three levels of evidence should be distinguished: target-dependent signal generation, validated measurement in a defined specimen, and diagnostic discrimination against an independent clinical reference. Success at the first level does not establish the subsequent levels. Accordingly, detection limits and calibration curves substantiate aspects of analytical capability, whereas claims concerning cancer diagnosis, prognosis, or monitoring require evidence linking measurements to clinically defined outcomes.

The distribution of targets reveals an uneven evidence base. Multiple CEA platforms provide opportunities to compare recognition–transduction architectures, including impedimetric and other electrochemical immunosensors,80,81 fluorescence-based detection,84 and electrochemiluminescence immunosensing.85

However, repeated measurement of one biomarker expands architectural coverage more directly than biological coverage. Evidence for PCA3-associated sequences, CD44, p53, and CA 15-3 is represented by fewer configurations within the reviewed corpus.76,79,82 Consequently, platform diversity should not be interpreted as independent replication of a transferable design principle. Such replication would require comparable measurements across independently prepared materials, laboratories, and specimen populations.

Mechanistic confidence also requires assessment separately from analytical performance. A reproducible concentration-dependent response may support calibration while remaining compatible with several physical explanations. For example, fluorescence recovery, increased charge-transfer resistance, and catalytic current modulation describe different observables; none alone identifies a unique contribution from GQD–Au coupling.80,84,89 Mechanistic claims become more persuasive when component controls, recognition controls, and independent measurements converge on the same explanation. Where several components or fabrication parameters change simultaneously, the defensible conclusion concerns the performance of the complete architecture rather than the isolated superiority of a particular dopant, gold morphology, or constituent interface.

Biological-matrix evidence should be classified according to specimen origin, target origin, and sample processing. Measurements in buffer establish analytical behavior under controlled conditions. Recovery experiments in target-spiked serum examine the measurement of an added analyte within a specified matrix. Measurements of endogenous biomarkers address naturally occurring analytes, including their native molecular associations and biological variability. Diagnostic evaluation additionally requires clinically characterized specimens and an independent reference defining disease status or the intended clinical endpoint.73–75 These forms of evidence are complementary, but they support different conclusions.

The reviewed platforms illustrate why matrix identity and dilution must accompany performance values. For PSA, the reported LOD increases from 0.29 fg mL−1 in PBS to 26 fg mL−1 in neat human serum, despite serum recoveries of 97–107%.78 Favorable recovery therefore does not imply preservation of buffer-based detection capability. The N,S-GQD/Au–polyaniline CEA study uses tenfold-diluted human serum,80 whereas the AuNP/N-GQD/rGO platform evaluates CEA added to fetal bovine serum with fiftyfold dilution.81 These experiments support performance under their respective preparation conditions; they do not establish equivalent behavior in undiluted human specimens.

Practical diagnostic applicability should therefore be assessed using endogenous-analyte measurements in specimens representing the intended population, including appropriate controls and relevant comorbid conditions. Reference-method comparison establishes measurement agreement, while diagnostic sensitivity, specificity, and decision thresholds require evaluation against clinical status. Spike recovery alone cannot provide these diagnostic quantities. Similarly, commercial serum, fetal bovine serum, and cultured-cell lysates should retain their specific designations rather than being grouped as clinical validation. Reporting specimen provenance, dilution, pretreatment, analyte origin, and comparator methods makes the progression from matrix compatibility to diagnostic evidence explicit.73–75

Multiplexing and intact-cell sensing introduce additional requirements. Simultaneous measurement of three microRNAs demonstrates analytical channel separation, but improved diagnostic information must be established by comparing the combined measurements with individual markers against an independent clinical endpoint.77 For cell assays, concentration sensitivity must be considered together with processed volume, capture recovery, background-cell interference, and verified cell identity.87–89 Cell-line detection and lysate analysis provide useful experimental evidence, but neither independently establishes reliable detection of patient-derived circulating tumor cells.

Overall, the reviewed corpus supports architectural versatility and target-responsive measurement under specified conditions. Its strongest contribution is the demonstration of alternative ways to integrate recognition, capture, and transduction. The principal unresolved question is how consistently these capabilities transfer across material batches, specimen environments, and clinically relevant populations. Addressing that question requires study-specific appraisal of precision, reference-method agreement, independent replication, and diagnostic outcomes. These criteria provide a firmer basis for judging progress than either increasing material complexity or decreasing the reported detection limit alone.

Table 2 provides a representative comparison of the 13 primary studies discussed in this review, rather than an exhaustive inventory of GQD–Au cancer sensors. Its organizing rationale is to illustrate variation in recognition targets, constituent arrangements, readout mechanisms, and biological-matrix testing. The selected examples encompass nucleic-acid, protein, and intact-cell assays; direct, supported, and multicomponent architectures; and electrochemical, fluorescence, and electrochemiluminescence responses. Multiple CEA platforms are retained because they illustrate different interfacial and transduction arrangements for the same target, permitting architectural comparison without treating each platform as an independent expansion of biological coverage. Reported detection limits are considered alongside calibration intervals, specimen identity, and available application evidence. Buffer-only demonstrations and incompletely validated assays remain informative for identifying evidence gaps, but their inclusion does not establish clinical applicability. The distribution of targets and readout formats in the table describes this representative study set and should not be interpreted as a quantitative survey of the field.

5. Beyond proof of concept: unresolved barriers and research priorities

5.1. GQD batch heterogeneity and transferable interface design

For GQD–Au sensors, reproducibility begins before electrode fabrication or bioconjugation. Nominally identical GQD preparations may differ in size distribution, oxidation, heteroatom bonding environments, accessible functional groups, and residual synthesis products. These descriptors should therefore be measured and retained as batch-level information rather than represented solely by a formulation name.90,93 In the assembled sensor, the relevant question is whether such variation changes gold deposition, receptor loading, optical background, or electrochemical response.

A practical qualification strategy should compare independently synthesized GQD batches using the same gold preparation, recognition reagent, substrate, and assay protocol. The resulting hybrids should be assessed for constituent organization, accessible recognition capacity, blank response, calibration slope, and measurement precision. Reference materials can support characterization but do not replace testing of the functional composite.94

Computational optimization should incorporate this batch structure. Nanoplasmonic modelling and synthesis-learning approaches offer useful methods,91,92 but predictive performance should be evaluated on batches excluded from model development. A transferable design relationship must retain predictive value when the material preparation changes, rather than reproduce repeated measurements from one optimized batch.

5.2. Au–thiol attachment and operational interface stability

Au–thiol attachment requires stability assessment under the conditions in which the complete sensor operates. Evidence from gold-supported electrochemical aptamer sensors demonstrates that monolayer integrity can depend on temperature, biological medium, molecular packing, and electrochemical interrogation; suitable surface chemistry and operating conditions can also extend functional lifetime.96 This evidence provides a chemical precedent rather than direct proof of identical degradation in GQD–Au cancer sensors.

Where thiol chemistry anchors GQDs, recognition probes, or blocking molecules to gold, these attachment roles should be evaluated separately. Loss of a recognition probe, rearrangement of a blocking layer, and detachment of a GQD-containing component can produce different analytical consequences. Baseline drift alone cannot identify which process occurred.

Testing should therefore combine time-dependent assay performance with measurements of retained surface loading or released components where feasible. Comparisons should include buffer and the intended biological matrix, storage and measurement temperatures, and the actual potential window or optical exposure. Proposed stabilizing modifications must preserve receptor accessibility and signal transduction. Retention of a material signal or baseline current is insufficient if target-dependent response deteriorates.

5.3. Scaling GQD–Au assembly and device manufacturing

Scaling GQD–Au preparation requires preservation of constituent arrangement and surface accessibility, alongside production yield. For solution-grown hybrids, process qualification should examine mixing, precursor addition, reaction history, purification, and the resulting gold morphology and GQD coverage. For electrodeposited or supported assemblies, deposition charge, substrate variability, drying, and coating uniformity become additional process variables. Screen-printed platforms provide a relevant fabrication route, but compatibility with the complete GQD–Au recognition interface must be demonstrated.95

Manufacturing studies should distinguish variation among GQD synthesis batches, hybrid-assembly batches, and devices fabricated from one preparation. Release criteria should connect material descriptors with analytical outcomes, including blank variability, calibration slope, recognition capacity, and between-device precision. A higher synthesis yield does not establish reproducible sensor manufacture.

Cost assessment should include purification losses, gold consumption, recognition reagents, rejected devices, packaging, and quality-control measurements. Substitution of precursors, substrates, or reagent suppliers should be treated as a process change requiring verification.97 The practical objective is a reproducible analytical function across production lots, rather than preservation of nominal composition alone.

5.4. Point-of-care formats and intended-use performance

Point-of-care development requires integration of GQD–Au chemistry into a defined specimen-to-result workflow. Candidate electrochemical formats include disposable screen-printed electrodes and microfluidic cartridges coupled to portable readers. Optical formats require controlled excitation, collection geometry, background correction, and calibration. These are development options whose suitability must be established for the selected assay, rather than inferred from a low laboratory LOD.98,99

For GQD–Au assemblies, device integration should evaluate whether drying, storage, and rehydration preserve colloidal organization, interfacial attachment, receptor activity, and calibration. Blood-cell separation, dilution, washing, and waste containment must be included when required. Reported turnaround time should cover these operations as well as signal acquisition.

Performance should be assessed using the intended specimen, sample volume, operator, and environmental conditions, with comparison against an appropriate reference procedure. Spiked-sample recovery should remain distinct from endogenous-biomarker measurement and diagnostic classification. If computational classification is incorporated, evaluation should separate patients and device lots between development and testing, with appropriate reporting guidance.100,101 A point-of-care claim ultimately requires reliable operation of the integrated assay under its intended conditions.

6. Conclusion

GQD–Au cancer sensors combine target recognition with optical or electrochemical readouts. Their performance depends on the complete assembly, including supporting materials, recognition probes, reporters, and sample preparation. Comparisons should therefore identify what each constituent contributes before assigning improved performance to GQD–Au coupling.

The reviewed studies demonstrate several sensing architectures, but their evidence supports different conclusions. Component comparisons test whether a formulation improves the measured response. Spectroscopy and electrochemical measurements examine proposed mechanisms. Calibration, independent-device precision, matrix testing, and reference-method comparisons assess measurement reliability. These forms of evidence are complementary. A low calculated LOD does not establish reliable detection near that concentration, and recovery from spiked samples does not establish diagnostic accuracy. Development priorities include reproducible GQD batches, stable attachment chemistry, consistent gold deposition and receptor loading, and scalable device fabrication. Point-of-care development additionally requires reliable storage, rehydration, sample handling, and portable signal acquisition. Future studies should connect these process variables to predefined analytical requirements and evaluate performance across independently prepared batches and representative specimens. This approach would establish which GQD–Au designs maintain useful performance beyond an individual laboratory demonstration.

Conflicts of interest

There are no conflicts to declare.

Acknowledgments

The authors extend their appreciation to the Academic Innovation Leadership Program under the King Khalid University Developmental Project for Stimulating Sustainable Innovation Ecosystems toward Future Manufacturing through the project code VPGSR/FM/PG50.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

References

  1. Singh S. Podder P. S. Russo M. Henry C. Cinti S. Tailored point-of-care biosensors for liquid biopsy in the field of oncology. Lab Chip. 2023;23:44–61. doi: 10.1039/D2LC00666A. [DOI] [PubMed] [Google Scholar]
  2. Lyu N. Hassanzadeh-Barforoushi A. Rey Gomez L. M. Zhang W. Wang Y. SERS biosensors for liquid biopsy towards cancer diagnosis by detection of various circulating biomarkers: current progress and perspectives. Nano Convergence. 2024;11:22. doi: 10.1186/s40580-024-00428-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Putri A. D. Murti B. T. Manga Y. B. Kanchi S. Huang Y.-J. Peng C.-W. Yang P.-K. Hsieh C.-M. Whole-Cell Electrochemical Aptasensors for Cancer Diagnosis: Current Advances and Prospects. Adv. Sens. Res. 2024;3:2300151. doi: 10.1002/adsr.202300151. [DOI] [Google Scholar]
  4. Ben Moussa F. Kutner W. Beduk T. Sena-Torralba A. Mostafavi E. Electrochemical bio- and chemosensors for cancer biomarkers: Natural (with antibodies) versus biomimicking artificial (with aptamers and molecularly imprinted polymers) recognition. Talanta. 2024;267:125259. doi: 10.1016/j.talanta.2023.125259. [DOI] [PubMed] [Google Scholar]
  5. Bhardwaj H. Archana S. Noumani A. Himanshu J. K. Chakravorty S. Solanki P. R. Recent advancement in the detection of potential cancer biomarkers using the nanomaterial integrated electrochemical sensing technique: a detailed review. Mater. Adv. 2024;5:475–503. doi: 10.1039/D3MA00621B. [DOI] [Google Scholar]
  6. Sarkar S. Hazra S. Patra S. Gogoi M. Biosensors for cancer detection: A review. TrAC, Trends Anal. Chem. 2024;180:117978. doi: 10.1016/j.trac.2024.117978. [DOI] [Google Scholar]
  7. Fam M. K. Ismail N. I. Zahari A. I. Ghazali N. A. Hassan N. Biosensor technologies in cancer: tools for early detection and prognostic monitoring. Biomark. Res. 2026;14:8. doi: 10.1186/s40364-025-00884-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pourmadadi M. Soleimani Dinani H. Saeidi Tabar F. Khassi K. Janfaza S. Tasnim N. Hoorfar M. Properties and Applications of Graphene and Its Derivatives in Biosensors for Cancer Detection: A Comprehensive Review. Biosensors. 2022;12:269. doi: 10.3390/bios12050269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Alsharabi R. M. Rai S. Mohammed H. Y. Farea M. A. Srinivasan S. Saxena P. S. Srivastava A. A comprehensive review on graphene-based materials as biosensors for cancer detection. Oxford Open Mater. Sci. 2023;3:itac013. doi: 10.1093/oxfmat/itac013. [DOI] [Google Scholar]
  10. Baruah A. Newar R. Das S. Kalita N. Nath M. Ghosh P. Chinnam S. Sarma H. Narayan M. Biomedical applications of graphene-based nanomaterials: recent progress, challenges, and prospects in highly sensitive biosensors. Discover Nano. 2024;19:103. doi: 10.1186/s11671-024-04032-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nesakumar N. Srinivasan S. Alwarappan S. Graphene quantum dots: synthesis, properties, and applications to the development of optical and electrochemical sensors for chemical sensing. Microchim. Acta. 2022;189:258. doi: 10.1007/s00604-022-05353-y. [DOI] [PubMed] [Google Scholar]
  12. Ravi P. V. Subramaniyam V. Saravanakumar N. Pattabiraman A. Pichumani M. What works and what doesn't when graphene quantum dots are functionalized for contemporary applications? Coord. Chem. Rev. 2023;493:215270. doi: 10.1016/j.ccr.2023.215270. [DOI] [Google Scholar]
  13. Jan A. Batool M. Akram S. Malik A. H. Khanday W. A. Wani W. A. Sheikh R. A. Rather J. A. Kannan P. Functionalized Graphene Quantum Dots (FGQDs): A review of their synthesis, properties, and emerging biomedical applications. Carbon Trends. 2025;18:100442. doi: 10.1016/j.cartre.2024.100442. [DOI] [Google Scholar]
  14. Kansara V. Shukla R. Flora S. J. S. Bahadur P. Tiwari S. Graphene quantum dots: Synthesis, optical properties and navigational applications against cancer. Mater. Today Commun. 2022;31:103359. doi: 10.1016/j.mtcomm.2022.103359. [DOI] [Google Scholar]
  15. Suresh R. R. Kulandaisamy A. J. Nesakumar N. Nagarajan S. Lee J. H. Rayappan J. B. B. Graphene Quantum Dots – Hydrothermal Green Synthesis, Material Characterization and Prospects for Cervical Cancer Diagnosis Applications: A Review. ChemistrySelect. 2022;7:e202200655. doi: 10.1002/slct.202200655. [DOI] [Google Scholar]
  16. Campuzano S. Yáñez-Sedeño P. Pingarrón J. M. Carbon Dots and Graphene Quantum Dots in Electrochemical Biosensing. Nanomaterials. 2019;9:634. doi: 10.3390/nano9040634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Li C.-H. Chan M.-H. Chang Y.-C. Hsiao M. Gold Nanoparticles as a Biosensor for Cancer Biomarker Determination. Molecules. 2023;28:364. doi: 10.3390/molecules28010364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liu L. Xiong H. Wang X. Jiang H. Gold nanomaterials: important vectors in biosensing of breast cancer biomarkers. Anal. Bioanal. Chem. 2024;416:3869–3885. doi: 10.1007/s00216-024-05151-w. [DOI] [PubMed] [Google Scholar]
  19. Kumalasari M. R. Alfanaar R. Andreani A. S. Gold nanoparticles (AuNPs): A versatile material for biosensor application. Talanta Open. 2024;9:100327. doi: 10.1016/j.talo.2024.100327. [DOI] [Google Scholar]
  20. Sultana E. Mamun M. S. A. Toward point-of-care cancer diagnostics: gold nanoparticle-based colorimetric sensors. RSC Adv. 2026;16:34422–34450. doi: 10.1039/D6RA03674K. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dar M. S. Sahu N. K. Graphene quantum dot-crafted nanocomposites: shaping the future landscape of biomedical advances. Discover Nano. 2024;19:79. doi: 10.1186/s11671-024-04028-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ja’farawy M. S. A. Thirumalai D. Lee J. Jung H. S. Chang S.-C. Yoon J.-H. Kim D.-H. Graphene quantum dot nanocomposites: electroanalytical and optical sensor technology perspective. J. Anal. Sci. Technol. 2023;14:29. doi: 10.1186/s40543-023-00393-2. [DOI] [Google Scholar]
  23. Song G. Han H. Ma Z. Anti-Fouling Strategies of Electrochemical Sensors for Tumor Markers. Sensors. 2023;23:5202. doi: 10.3390/s23115202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saxena S. Sen P. Soleymani L. Hoare T. Anti-Fouling Polymer or Peptide-Modified Electrochemical Biosensors for Improved Biosensing in Complex Media. Adv. Sens. Res. 2024;3:2300170. doi: 10.1002/adsr.202300170. [DOI] [Google Scholar]
  25. Mikaeeli Kangarshahi B. Sojdeh S. Daneshgar H. Bagherzadeh M. Naghib S. M. Rabiee N. Electroconductive polymer-based biosensors for early cancer detection via liquid biopsy: Advances, challenges, and future prospects. TrAC, Trends Anal. Chem. 2025;183:118062. doi: 10.1016/j.trac.2024.118062. [DOI] [Google Scholar]
  26. Iannazzo D. Espro C. Celesti C. Ferlazzo A. Neri G. Smart Biosensors for Cancer Diagnosis Based on Graphene Quantum Dots. Cancers. 2021;13:3194. doi: 10.3390/cancers13133194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tabish T. A. Hayat H. Abbas A. Narayan R. J. Graphene quantum dot–based electrochemical biosensing for early cancer detection. Curr. Opin. Electrochem. 2021;30:100786. doi: 10.1016/j.coelec.2021.100786. [DOI] [Google Scholar]
  28. Rasheed P. A. Ankitha M. Pillai V. K. Alwarappan S. Graphene quantum dots for biosensing and bioimaging. RSC Adv. 2024;14:16001–16023. doi: 10.1039/D4RA01431F. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tai J. Fan S. Ding S. Ren L. Gold Nanoparticles Based Optical Biosensors for Cancer Biomarker Proteins: A Review of the Current Practices. Front. Bioeng. Biotechnol. 2022;10:877193. doi: 10.3389/fbioe.2022.877193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Beygisangchin M. Jakmunee J. Kungwan N. Ounnunkad K. Sangthong P. Baghdadi A. H. Kamarudin S. K. Graphene Quantum Dot-Based Biosensors: Recent Advances in Functionalization Strategies and Biomedical Applications. Biosensors. 2026;16:249. doi: 10.3390/bios16050249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Panda S. Devi K. S. S. Tsujimura S. Kumar S. Jakmunee J. Prakash J. Recent advances in graphene quantum dots: Chemistry of synthesis, surface modifications, and improved properties for biomedical applications. TrAC, Trends Anal. Chem. 2025;191:118293. doi: 10.1016/j.trac.2025.118293. [DOI] [Google Scholar]
  32. Rabeya R. Mahalingam S. Manap A. Satgunam M. Akhtaruzzaman M. Chia C. H. Structural defects in graphene quantum dots: A review. Int. J. Quantum Chem. 2022;122:e26900. doi: 10.1002/qua.26900. [DOI] [Google Scholar]
  33. Im M. J. Kim J. I. Hyeong S.-K. Moon B. J. Bae S. From Pristine to Heteroatom-Doped Graphene Quantum Dots: An Essential Review and Prospects for Future Research. Small. 2023;19:2304497. doi: 10.1002/smll.202304497. [DOI] [PubMed] [Google Scholar]
  34. Kansara V. Tiwari S. Patel M. Graphene quantum dots: A review on the effect of synthesis parameters and theranostic applications. Colloids Surf., B. 2022;217:112605. doi: 10.1016/j.colsurfb.2022.112605. [DOI] [PubMed] [Google Scholar]
  35. Kumar P. Dhand C. Dwivedi N. Singh S. Khan R. Verma S. Singh A. Gupta M. K. Kumar S. Kumar R. Srivastava A. K. Graphene quantum dots: A contemporary perspective on scope, opportunities, and sustainability. Renewable Sustainable Energy Rev. 2022;157:111993. doi: 10.1016/j.rser.2021.111993. [DOI] [Google Scholar]
  36. Dahan K. A. Li Y. Xu J. Kan C. Recent progress of gold nanostructures and their applications. Phys. Chem. Chem. Phys. 2023;25:18545–18576. doi: 10.1039/D3CP01549A. [DOI] [PubMed] [Google Scholar]
  37. Du X. Liu Z. Higaki T. Zhou M. Jin R. Understanding nascent plasmons and metallic bonding in atomically precise gold nanoclusters. Chem. Sci. 2022;13:1925–1932. doi: 10.1039/D1SC06819A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Cheng D. Liu R. Hu K. Gold nanoclusters: Photophysical properties and photocatalytic applications. Front. Chem. 2022;10:958626. doi: 10.3389/fchem.2022.958626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Becerril-Castro I. B. Calderon I. Pazos-Perez N. Guerrini L. Schulz F. Feliu N. Chakraborty I. Giannini V. Parak W. J. Alvarez-Puebla R. A. Gold Nanostars: Synthesis, Optical and SERS Analytical Properties. Analysis Sensing. 2022;2:e202200005. doi: 10.1002/anse.202200005. [DOI] [Google Scholar]
  40. Matus M. F. Häkkinen H. Understanding ligand-protected noble metal nanoclusters at work. Nat. Rev. Mater. 2023;8:372–389. doi: 10.1038/s41578-023-00537-1. [DOI] [Google Scholar]
  41. Schulz F. Hühn J. Werner M. Hühn D. Kvelstad J. Koert U. Wutke N. Klapper M. Fröba M. Baulin V. Parak W. J. Local Environments Created by the Ligand Coating of Nanoparticles and Their Implications for Sensing and Surface Reactions. Acc. Chem. Res. 2023;56:2278–2285. doi: 10.1021/acs.accounts.3c00139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Thai V.-P. Nguyen H. D. Saito N. Takahashi K. Sasaki T. Kikuchi T. Precise size-control and functionalization of gold nanoparticles synthesized by plasma–liquid interactions: using carboxylic, amino, and thiol ligands. Nanoscale Adv. 2022;4:4490–4501. doi: 10.1039/D2NA00542E. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Chen W. Shen J. Chen S. Yan J. Zhang N. Zheng K. Liu X. Synthesis of graphene quantum dot-stabilized gold nanoparticles and their application. RSC Adv. 2019;9:21215–21219. doi: 10.1039/C9RA02758K. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Mazloum-Ardakani M. Aghaei R. Abdollahi-Alibeik M. Moaddeli A. Fabrication of modified glassy carbon electrode using graphene quantum dot, gold nanoparticles and 4-(((4-mercaptophenyl)imino)methyl) benzene-1,2-diol by self-assembly method and investigation of their electrocatalytic activities. J. Electroanal. Chem. 2015;738:113–122. doi: 10.1016/j.jelechem.2014.11.021. [DOI] [Google Scholar]
  45. Hou G. Pan Y. Qiao L. Ran X. Li T. Chi Z. Liu P. He Y. Kuang Y. Guo L. Band alignment driven efficient electron transfer and enhanced photoelectric property of gold nanoclusters sensitized graphene quantum dot composites. J. Alloys Compd. 2023;969:172261. doi: 10.1016/j.jallcom.2023.172261. [DOI] [Google Scholar]
  46. Rafati N. Hashemzadeh H. Jafarzadeh S. Saievar-Iranizad E. Naderi-Manesh H. Novel surfactant-free electro-nanofabricating strategy for highly sensitive and selective colorectal cancer MicroRNA analysis. Microchem. J. 2024;207:112233. doi: 10.1016/j.microc.2024.112233. [DOI] [Google Scholar]
  47. Dridi N. Jin Z. Perng W. Mattoussi H. Probing Protein Corona Formation around Gold Nanoparticles: Effects of Surface Coating. ACS Nano. 2024;18:8649–8662. doi: 10.1021/acsnano.3c08005. [DOI] [PubMed] [Google Scholar]
  48. Nienhaus K. Nienhaus G. U. Mechanistic Understanding of Protein Corona Formation around Nanoparticles: Old Puzzles and New Insights. Small. 2023;19:2301663. doi: 10.1002/smll.202301663. [DOI] [PubMed] [Google Scholar]
  49. Bashiri G. Padilla M. S. Swingle K. L. Shepherd S. J. Mitchell M. J. Wang K. Nanoparticle protein corona: from structure and function to therapeutic targeting. Lab Chip. 2023;23:1432–1466. doi: 10.1039/D2LC00799A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hajipour M. J. Safavi-Sohi R. Sharifi S. Mahmoud N. Ashkarran A. A. Voke E. Serpooshan V. Ramezankhani M. Milani A. S. Landry M. P. Mahmoudi M. An Overview of Nanoparticle Protein Corona Literature. Small. 2023;19:2301838. doi: 10.1002/smll.202301838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Arshavsky-Graham S. Heuer C. Jiang X. Segal E. Aptasensors versus immunosensors—Which will prevail? Eng. Life Sci. 2022;22:319–333. doi: 10.1002/elsc.202100148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Gan S. Y. Tye G. J. Chew A. L. Ng W. K. Lai N. S. Linker-mediated oriented antibody immobilisation strategies for a more efficient immunosensor and diagnostic applications: A review. Biosens. Bioelectron.:X. 2023;14:100379. doi: 10.1016/j.biosx.2023.100379. [DOI] [Google Scholar]
  53. Yang L. F. Ling M. Kacherovsky N. Pun S. H. Aptamers 101: aptamer discovery and in vitro applications in biosensors and separations. Chem. Sci. 2023;14:4961–4978. doi: 10.1039/D3SC00439B. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Meng X. O'Hare D. Ladame S. Surface immobilization strategies for the development of electrochemical nucleic acid sensors. Biosens. Bioelectron. 2023;237:115440. doi: 10.1016/j.bios.2023.115440. [DOI] [PubMed] [Google Scholar]
  55. McCann B. Tipper B. Shahbeigi S. Soleimani M. Jabbari M. Nasr Esfahani M. A Review on Perception of Binding Kinetics in Affinity Biosensors: Challenges and Opportunities. ACS Omega. 2025;10:4197–4216. doi: 10.1021/acsomega.4c10040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hildebrandt N. Lim M. Kim N. Choi D. Y. Nam J.-M. Plasmonic quenching and enhancement: metal–quantum dot nanohybrids for fluorescence biosensing. Chem. Commun. 2023;59:2352–2380. doi: 10.1039/D2CC06178C. [DOI] [PubMed] [Google Scholar]
  57. Liu X. Luo Y. Zhang Y. Xie Z. Xu C. Gold nanoparticle-mediated fluorescence resonance energy transfer for analytical applications in the fields of life health and safety. Talanta. 2025;282:127023. doi: 10.1016/j.talanta.2024.127023. [DOI] [PubMed] [Google Scholar]
  58. Weitner T. Friganović T. Šakić D. Inner Filter Effect Correction for Fluorescence Measurements in Microplates Using Variable Vertical Axis Focus. Anal. Chem. 2022;94:7107–7114. doi: 10.1021/acs.analchem.2c01031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Yang E. Zhang Y. Shen Y. Quantum dots for electrochemiluminescence bioanalysis - A review. Anal. Chim. Acta. 2022;1209:339140. doi: 10.1016/j.aca.2021.339140. [DOI] [PubMed] [Google Scholar]
  60. Kalkal A. Pradhan R. Kadian S. Manik G. Packirisamy G. Biofunctionalized graphene quantum dots based fluorescent biosensor toward efficient detection of small cell lung cancer. ACS Appl. Bio Mater. 2020;3:4922–4932. doi: 10.1021/acsabm.0c00427. [DOI] [PubMed] [Google Scholar]
  61. Brett C. M. A. Electrochemical Impedance Spectroscopy in the Characterisation and Application of Modified Electrodes for Electrochemical Sensors and Biosensors. Molecules. 2022;27:1497. doi: 10.3390/molecules27051497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yang Y. Liu Q. Liu Y. Cui J. Liu H. Wang P. Li Y. Chen L. Zhao Z. Dong Y. A novel label-free electrochemical immunosensor based on functionalized nitrogen-doped graphene quantum dots for carcinoembryonic antigen detection. Biosens. Bioelectron. 2017;90:31–38. doi: 10.1016/j.bios.2016.11.029. [DOI] [PubMed] [Google Scholar]
  63. Weaver S. Mohammadi M. H. Nakatsuka N. Aptamer-functionalized capacitive biosensors. Biosens. Bioelectron. 2023;224:115014. doi: 10.1016/j.bios.2022.115014. [DOI] [PubMed] [Google Scholar]
  64. Phetsang S. Jouanne C. Mallouki M. Pham-Truong T.-N. Peralta S. Vancaeyzeele C. Banet P. Aubert P.-H. Jakmunee J. Ounnunkad K. Competitive electrochemical assay of CA19-9 on gold nanoparticles/porous carbons nanohybrid amplified by polyoxometalate/aptamer/graphene quantum dot-decorated gold nanotags. J. Mater. Chem. B. 2025;13:11652–11662. doi: 10.1039/D5TB01565K. [DOI] [PubMed] [Google Scholar]
  65. Verrinder E. Leung K. K. Erdal M. K. Sepunaru L. Plaxco K. W. Comparison of voltammetric methods used in the interrogation of electrochemical aptamer-based sensors. Sens. Diagn. 2024;3:95–103. doi: 10.1039/D3SD00083D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Goodrum R. Li H. Advances in three dimensional metal enhanced fluorescence based biosensors using metal nanomaterial and nano-patterned surfaces. Biotechnol. J. 2024;19:e2300519. doi: 10.1002/biot.202300519. [DOI] [PubMed] [Google Scholar]
  67. Condict L. Kasapis S. Critical issues encountered in the analysis of protein-phenolic binding interactions via fluorescence spectroscopy. Food Hydrocolloids. 2022;124:107219. doi: 10.1016/j.foodhyd.2021.107219. [DOI] [Google Scholar]
  68. Lazanas A. Ch. Prodromidis M. I. Electrochemical Impedance Spectroscopy—A Tutorial. ACS Meas. Sci. Au. 2023;3:162–193. doi: 10.1021/acsmeasuresciau.2c00070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Fontaine N. Dauphin-Ducharme P. Confounding effects on the response of electrochemical aptamer-based biosensors. Curr. Opin. Electrochem. 2023;41:101361. doi: 10.1016/j.coelec.2023.101361. [DOI] [Google Scholar]
  70. López Marzo A. M. Techniques for characterizing biofunctionalized surfaces for bioanalysis purposes. Biosens. Bioelectron. 2024;263:116599. doi: 10.1016/j.bios.2024.116599. [DOI] [PubMed] [Google Scholar]
  71. Moulahoum H. Ghorbanizamani F. The LOD paradox: When lower isn't always better in biosensor research and development. Biosens. Bioelectron. 2024;264:116670. doi: 10.1016/j.bios.2024.116670. [DOI] [PubMed] [Google Scholar]
  72. Chadha U. Bhardwaj P. Agarwal R. Rawat P. Agarwal R. Gupta I. Panjwani M. Singh S. Ahuja C. Selvaraj S. K. Banavoth M. Sonar P. Badoni B. Chakravorty A. Recent progress and growth in biosensors technology: A critical review. J. Ind. Eng. Chem. 2022;109:21–51. doi: 10.1016/j.jiec.2022.02.010. [DOI] [Google Scholar]
  73. Gruson D. Cobbaert C. Dabla P. K. Stankovic S. Homsak E. Kotani K. Assaad R. S. Nichols J. H. Gouget B. Validation and verification framework and data integration of biosensors and in vitro diagnostic devices: a position statement of the IFCC Committee on Mobile Health and Bioengineering in Laboratory Medicine (C-MBHLM) and the IFCC Scientific Division. Clin. Chem. Lab. Med. 2024;62:1904–1917. doi: 10.1515/cclm-2023-1455. [DOI] [PubMed] [Google Scholar]
  74. Eurachem Guide: the Fitness for Purpose of Analytical Methods—A Laboratory Guide to Method Validation and Related Topics, ed. H. Cantwell, Eurachem, 3rd edn, 2025, https://www.eurachem.org/index.php/publications/guides/mv [Google Scholar]
  75. Planning and Reporting Method Validation Studies—Supplement to Eurachem Guide on the Fitness for Purpose of Analytical Methods, ed. V. Barwick, Eurachem, 2nd edn, 2025, https://www.eurachem.org/index.php/publications/guides/planning-validation-studies [Google Scholar]
  76. Raj D. Kumar A. Kumar D. Kant K. Mathur A. Gold–Graphene Quantum Dot Hybrid Nanoparticle for Smart Diagnostics of Prostate Cancer. Biosensors. 2024;14:534. doi: 10.3390/bios14110534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Pothipor C. Jakmunee J. Bamrungsap S. Ounnunkad K. An electrochemical biosensor for simultaneous detection of breast cancer clinically related microRNAs based on a gold nanoparticles/graphene quantum dots/graphene oxide film. Analyst. 2021;146:4000–4009. doi: 10.1039/D1AN00436K. [DOI] [PubMed] [Google Scholar]
  78. Tran H. L. Darmanto W. Doong R.-A. Electrochemical immunosensor for ultra-sensitive detection of attomolar prostate specific antigen with sulfur-doped graphene quantum dot@gold nanostar as the probe. Electrochim. Acta. 2021;389:138700. doi: 10.1016/j.electacta.2021.138700. [DOI] [Google Scholar]
  79. Kumar N. Sadique M. A. Khan R. Gowri V. S. Kumar S. Ashiq M. Natarajan S. Immunosensor for breast cancer CD44 biomarker detection based on exfoliated graphene quantum dots integrated gold nanoparticles. Hybrid Adv. 2023;3:100065. doi: 10.1016/j.hybadv.2023.100065. [DOI] [Google Scholar]
  80. Ganganboina A. B. Doong R.-A. Graphene Quantum Dots Decorated Gold-Polyaniline Nanowire for Impedimetric Detection of Carcinoembryonic Antigen. Sci. Rep. 2019;9:7214. doi: 10.1038/s41598-019-43740-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Yan Z. Wang L. Yan F. In Situ Growth of Au NPs on Nitrogen-Doped Graphene Quantum Dots Decorated Graphene Composites for the Construction of an Electrochemical Immunosensor and Its Application in CEA Detection. Molecules. 2025;30:1347. doi: 10.3390/molecules30061347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Hasanzadeh M. Baghban H. N. Shadjou N. Mokhtarzadeh A. Ultrasensitive electrochemical immunosensing of tumor suppressor protein p53 in unprocessed human plasma and cell lysates using a novel nanocomposite based on poly-cysteine/graphene quantum dots/gold nanoparticle. Int. J. Biol. Macromol. 2018;107:1348–1363. doi: 10.1016/j.ijbiomac.2017.11.006. [DOI] [PubMed] [Google Scholar]
  83. Hasanzadeh M. Tagi S. Solhi E. Mokhtarzadeh A. Shadjou N. Eftekhari A. Mahboob S. An innovative immunosensor for ultrasensitive detection of breast cancer specific carbohydrate (CA 15-3) in unprocessed human plasma and MCF-7 breast cancer cell lysates using gold nanospear electrochemically assembled onto thiolated graphene quantum dots. Int. J. Biol. Macromol. 2018;114:1008–1017. doi: 10.1016/j.ijbiomac.2018.03.183. [DOI] [PubMed] [Google Scholar]
  84. Ng S. S. Lee H. L. Tran H. L. Doong R.-A. Composites of Gold Nanostars and Nitrogen- and Sulfur-Codoped Graphene Quantum Dots as Plasmon-Enhanced Immunosensors for Cancer Prognosis. ACS Appl. Nano Mater. 2024;7:18287–18298. doi: 10.1021/acsanm.3c03650. [DOI] [Google Scholar]
  85. Dong Y. Wu H. Shang P. Zeng X. Chi Y. Immobilizing water-soluble graphene quantum dots with gold nanoparticles for a low potential electrochemiluminescence immunosensor. Nanoscale. 2015;7:16366–16371. doi: 10.1039/C5NR04328J. [DOI] [PubMed] [Google Scholar]
  86. Nie G. Wang Y. Tang Y. Zhao D. Guo Q. A graphene quantum dots based electrochemiluminescence immunosensor for carcinoembryonic antigen detection using poly(5-formylindole)/reduced graphene oxide nanocomposite. Biosens. Bioelectron. 2018;101:123–128. doi: 10.1016/j.bios.2017.10.021. [DOI] [PubMed] [Google Scholar]
  87. Ganganboina A. B. Dega N. K. Tran H. L. Darmonto W. Doong R.-A. Application of sulfur-doped graphene quantum dots@gold-carbon nanosphere for electrical pulse-induced impedimetric detection of glioma cells. Biosens. Bioelectron. 2021;181:113151. doi: 10.1016/j.bios.2021.113151. [DOI] [PubMed] [Google Scholar]
  88. Wang X. Li X. Wang B. Xie Y. Cui X. Jiao J. Jiao J. Zhang Y. A label-free electrochemical biosensor based on graphene quantum dots-nanoporous gold nanocomposite for highly sensitive detection of glioma cell. Anal. Chim. Acta. 2025;1337:343555. doi: 10.1016/j.aca.2024.343555. [DOI] [PubMed] [Google Scholar]
  89. Ruiyi L. Tinling P. Hongxia C. Jinsong S. Zaijun L. Electrochemical detection of cancer cells in human blood using folic acid and glutamic acid-functionalized graphene quantum dot-palladium@gold as redox probe with excellent electrocatalytic activity and target recognition. Sens. Actuators, B. 2020;309:127709. doi: 10.1016/j.snb.2020.127709. [DOI] [Google Scholar]
  90. Wyrzykowska E. Mikolajczyk A. Lynch I. Jeliazkova N. Kochev N. Sarimveis H. Doganis P. Karatzas P. Afantitis A. Melagraki G. Serra A. Greco D. Subbotina J. Lobaskin V. Bañares M. A. Valsami-Jones E. Jagiello K. Puzyn T. Representing and describing nanomaterials in predictive nanoinformatics. Nat. Nanotechnol. 2022;17:924–932. doi: 10.1038/s41565-022-01173-6. [DOI] [PubMed] [Google Scholar]
  91. Masson J.-F. Biggins J. S. Ringe E. Machine learning for nanoplasmonics. Nat. Nanotechnol. 2023;18:111–123. doi: 10.1038/s41565-022-01284-0. [DOI] [PubMed] [Google Scholar]
  92. Tao H. Wu T. Aldeghi M. Wu T. C. Aspuru-Guzik A. Kumacheva E. Nanoparticle synthesis assisted by machine learning. Nat. Rev. Mater. 2021;6:701–716. doi: 10.1038/s41578-021-00337-5. [DOI] [Google Scholar]
  93. Sharifi S. Mahmoud N. N. Voke E. Landry M. P. Mahmoudi M. Importance of Standardizing Analytical Characterization Methodology for Improved Reliability of the Nanomedicine Literature. Nano-Micro Lett. 2022;14:172. doi: 10.1007/s40820-022-00922-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Abram S.-L. Tavernaro I. Johnston L. J. Zou S. Resch-Genger U. Nanoscale reference and test materials for the validation of characterization methods for engineered nanomaterials — current state, limitations, and needs. Anal. Bioanal. Chem. 2025;417:2405–2425. doi: 10.1007/s00216-024-05719-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Crapnell R. D. Banks C. E. Electroanalytical Overview: Screen-Printed Electrochemical Sensing Platforms. ChemElectroChem. 2024;11:e202400370. doi: 10.1002/celc.202400370. [DOI] [Google Scholar]
  96. Watkins Z. Karajic A. Young T. White R. Heikenfeld J. Week-long operation of electrochemical aptamer sensors: New insights into self-assembled monolayer degradation mechanisms and solutions for stability in serum at body temperature. ACS Sens. 2023;8:1119–1131. doi: 10.1021/acssensors.2c02403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Zhou G. Liu H. Commercial Translation of Electrochemical Biosensors: Supply Chain Strategy, Scale-Up Manufacturing, and Regulatory–Quality Considerations. Biosensors. 2026;16:112. doi: 10.3390/bios16020112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. D'Alton L. Souto D. E. P. Punyadeera C. Abbey B. Voelcker N. H. Hogan C. Silva S. M. A holistic pathway to biosensor translation. Sens. Diagn. 2024;3:1234–1246. doi: 10.1039/D4SD00088A. [DOI] [Google Scholar]
  99. Docherty N. Macdonald D. Gordon A. Dobrea A. Mani V. Fu Y. Pang S. Jimenez M. Corrigan D. K. Maximising the translation potential of electrochemical biosensors. Chem. Commun. 2025;61:13359–13377. doi: 10.1039/D5CC02322J. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Collins G. S. Moons K. G. M. Dhiman P. Riley R. D. Beam A. L. Van Calster B. Ghassemi M. Liu X. Reitsma J. B. van Smeden M. Boulesteix A.-L. Camaradou J. C. Celi L. A. Denaxas S. Denniston A. K. Glocker B. Golub R. M. Harvey H. Heinze G. Hoffman M. M. Kengne A. P. Lam E. Lee N. Loder E. W. Maier-Hein L. Mateen B. A. McCradden M. D. Oakden-Rayner L. Ordish J. Parnell R. Rose S. Singh K. Wynants L. Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi: 10.1136/bmj-2023-078378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Sounderajah V. Guni A. Liu X. Collins G. S. Karthikesalingam A. Markar S. R. Golub R. M. Denniston A. K. Shetty S. Moher D. Bossuyt P. M. Darzi A. Ashrafian H. STARD-AI Steering Committee, The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence. Nat. Med. 2025;31:3283–3289. doi: 10.1038/s41591-025-03953-8. [DOI] [PubMed] [Google Scholar]
  102. Gharehaghaji Z. H. Khalilzadeh B. Yousefi H. Mohammad-Rezaei R. An electrochemical immunosensor based on MXene-GQD/AuNPs for the detection of trace amounts of CA-125 as specific tracer of ovarian cancer. Microchim. Acta. 2024;191:418. doi: 10.1007/s00604-024-06469-z. [DOI] [PubMed] [Google Scholar]
  103. Centane S. Nyokong T. The antibody assisted detection of HER2 on a cobalt porphyrin binuclear framework and gold functionalized graphene quantum dots modified electrode. J. Electroanal. Chem. 2021;880:114908. doi: 10.1016/j.jelechem.2020.114908. [DOI] [Google Scholar]
  104. Centane S. Nyokong T. Aptamer versus antibody as probes for the impedimetric biosensor for human epidermal growth factor receptor. J. Inorg. Biochem. 2022;230:111764. doi: 10.1016/j.jinorgbio.2022.111764. [DOI] [PubMed] [Google Scholar]
  105. Shafaei S. Mohammad-Rezaei R. Khalilzadeh B. Photoelectrochemical immunosensing of prostate-specific antigen (PSA) based on co-electrodeposited polyaniline-graphene quantum dot-tungsten oxide nanocomposite decorated with gold nanoparticles. Biosens. Bioelectron. 2026;311:118888. doi: 10.1016/j.bios.2026.118888. [DOI] [PubMed] [Google Scholar]
  106. Miao X. Wen S. Su Y. Fu J. Luo X. Wu P. Cai C. Jelinek R. Jiang L.-P. Zhu J.-J. Graphene quantum dots wrapped gold nanoparticles with integrated enhancement mechanisms as sensitive and homogeneous substrates for surface-enhanced Raman spectroscopy. Anal. Chem. 2019;91:7295–7303. doi: 10.1021/acs.analchem.9b01001. [DOI] [PubMed] [Google Scholar]
  107. Nguyen T. K. A. Nguyen V. T. Huynh T. V. Huang Y.-H. Doong R.-A. Hsieh J. C.-H. Constructing an ultrasensitive electrochemical sensor based on N, S-codoped graphene quantum dots decorated Au-nanostar for MCF-7 breast cancer diagnostic. Chem. Eng. J. 2025;520:165771. doi: 10.1016/j.cej.2025.165771. [DOI] [Google Scholar]
  108. Wang L. Wang Y. Chen C. Li Y. Dong H. Yao T. Jin G. Wang Z. A sandwich-type electrochemical immunosensor based on gold nanoparticle-decorated ZIF-8 and N-doped graphene quantum dot labels for the ultrasensitive detection of breast cancer susceptibility protein 1 (BRCA1) Arabian J. Chem. 2026;19:14142025. doi: 10.25259/AJC_1414_2025. [DOI] [Google Scholar]
  109. Li K. Tu J. Zhang Y. Jin D. Li T. Li J. Ni W. Xiao M.-M. Zhang Z.-Y. Zhang G.-J. Ultrasensitive detection of exosomal miRNA with PMO-graphene quantum dots-functionalized field-effect transistor biosensor. iScience. 2022;25:104522. doi: 10.1016/j.isci.2022.104522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Tsai H. Lin W. Chuang M. Lu Y. Fuh C. B. Multifunctional nanoparticles for protein detections in thin channels. Biosens. Bioelectron. 2017;90:153–158. doi: 10.1016/j.bios.2016.11.023. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.


Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES